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Summary 
 
Differentiation of B lymphocytes requires the function of multiple transcription factors 
that determine lineage specification and commitment. Ebf1 is a key regulator of the 
transcriptional network in B cell development. It is expressed from common lymphoid 
progenitors (CLPs) to mature B cells. It participates in the regulation of 
immunoglobulin heavy chain D and J rearrangement and activates, represses and 
poises approximate 3000 target genes, which are involved in B cell development.  
 
To find an explanation for the diverse roles of Ebf1, post-translational modifications 
were studied. The phosphorylation of Ebf1 at serine13 and serine14 (S13 and S14) 
was discovered by mass spectrometry and we confirmed this finding in B cells. 
Phosphorylation of Ebf1 at both of these sites is required for early B cell development 
as substiution by alanine results in a strong developmental impairment. 
Phosphorylation of Ebf1-S13 and S14 does not influence DNA binding but is 
important for transactivation of target genes like Pax5. Interestingly, immunoglobulin 
heavy chain D and J rearrangement does not depend on phosphorylation of Ebf1-
S13 and S14.  
 
The expression of the Ebf1 gene results in two protein isoforms, αEbf1 and βEbf1. 
αEbf1 lacks 14 N-terminal amino acids of βEbf1, however, no functional difference 
between the two Ebf1 isoforms has yet been described. I find that αEbf1 regulates 
target genes from CLPs to pre-pro-B cells, such as Rag1, which mediates DJH 
rearrangement. The expression of βEbf1 starts from the pro-B stage and regulates 
Pax5, λ5, mb1, CD19 and VpreB in an Ebf1-S13 and S14 phosphorylation-
dependent manner. This data indicates that αEbf1 and βEbf1 regulate early B cell 
development at different stages by inducing different target genes. 
 
Taken together, my studies contribute to a better understanding of the diverse 
functions of Ebf1 and I show that the two Ebf1 isoforms are functionally different 
during early B cell development.  
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Zusammenfassung 
 
Die Differenzierung von B-Lymphozyten hängt von der Funktion mehrerer 
Transkriptionsfaktoren ab, welche diese Zellart spezifizieren und determinieren. Ebf1 
ist ein Schlüsselfaktor des transkriptionellen Netzwerks, und ist exprimiert von 
gemeinsamen lymphoiden Vorläuferzellen (CLP) bis zu reifen B-Zellen. Es reguliert 
die Umordnung der Immunglobulingene D und J, und aktiviert, reprimiert und 
beeinflußt ungefähr 3000 Zielgene, welche in der B Zellentwicklung eine Rolle 
spielen.  
 
Um eine Erklärung für die verschiedenen Rollen von Ebf1 zu finden, wurden post-
transkriptionelle Modifikationen untersucht. Die Phosphorylierung von Ebf1 an den 
Serinen 13 und 14 (S13, S14) wurde durch Massenspektroskopie entdeckt und hier 
unabhängig davon in B Zellen bestätigt. Der Austausch dieser beiden Aminosäuren 
durch Alanin resultiert in einer starken Verminderung der B Zellentwicklung, was die 
Wichtigkeit dieser Phosphoylierungen zeigt. Diese beeinflussen nicht die DNA-
Bindung, sind aber wichtig für die Transaktivierung von Zielgenen wie Pax5. 
Interessanterweise hängt die Umordnung der D und J Immunglobulingene jedoch 
nicht von dieser Phosphorylierung ab. 
 
Die Expression des Ebf1 Gens resultiert in zwei verschiedenen Proteinisoformen, 
αEbf1 und βEbf1. αEbf1 fehlen die ersten 14 Aminosäuren von βEbf1, bisher 
konnten jedoch keine funktionellen Unterschiede zwischen diesen zwei Isoformen 
gezeigt werden. Ich beschreibe hier die differentielle Regulierung verschiedener 
Zielgene, wie zum Beispiel von Rag1 in CLPs und die Umordnung der DJH 
Immunglobulingene durch αEbf1. Die Expression von βEbf1 beginnt im pro B-Zell 
Stadium und führt zur Regulation anderer Zielgene, wie zum Beispiel Pax5, λ5, mb1, 
CD19, und VpreB in Abhängigkeit der Phosphorylierung von S13 und S14. Diese 
Daten zeigen, daß αEbf1 und βEbf1 die frühe B Zellentwicklung in unterschiedlichen 
Stadien durch die Induktion verschiedener Zielgene regulieren.  
 
Zusammengenommen tragen diese Studien zu einem besseren Verständnis der 
Regulation der frühen B-Zellentwicklung durch differentielle Funktionen der beiden 
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Isoformen von Ebf1 bei. Erstmals können hier funktionelle Unterschiede zwischen 
αEbf1 und βEbf1 während dieser Entwicklung gezeigt werden. 
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1 Introduction 
1.1 The development of the hematopoietic system  
Hematopoietic stem cells (HSCs) can differentiate into all functional blood cells 
(Lemischka 1991, Seita and Weissman 2010, Spangrude et al. 1991). They are adult 
stem cells located in the bone marrow containing the potential for self-renewal and 
differentiation in a homeostatic balance (Becker, Mc and Till 1963, Chotinantakul and 
Leeanansaksiri 2012, Dzierzak and Medvinsky 2008, Till and Mc 1961)  
 
HSCs are divided into long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs). 
LT-HSCs possess self-renewing ability throughout life to generate sufficient numbers 
of ST-HSC. ST-HSCs maintain self-renewing ability for a limited time period and then 
develop into multipotent progenitors (MPPs) (Morrison and Weissman 1994, Seita 
and Weissman 2010, Weissman 2000).  MPPs lose self-renewal ability and start a 
functionally irreversible maturation process (Morrison and Weissman 1994, Seita and 
Weissman 2010, Christensen and Weissman 2001). Further downstream, MPPs 
develop into common lymphoid progenitors (CLPs) or common myeloid progenitors 
(CMPs) (Akashi et al. 2000, Karsunky et al. 2008, Kondo, Weissman and Akashi 
1997, Serwold, Ehrlich and Weissman 2009), loosing their lineage potential step by 
step until the progenitor becomes a mature functional cell. CLPs can develop into B 
cells, T cells, NK cells and dendritic cells (Karsunky et al. 2008, Kondo et al. 1997). 
CMPs can develop into platelets, erythrocyte, granulocytes and macrophages 
(Akashi et al. 2000). 
 
During mouse ontogeny the earliest HSC are found in the intra-embryonic aorta–
gonad–mesonephros (AGM) region of the 10 days old embryo (E10) (Medvinsky and 
Dzierzak 1996, Muller et al. 1994). From E11.5 on, HSCs are found in the yolk sac 
and the fetal liver (Huang and Auerbach 1993, Medvinsky and Dzierzak 1996, Moore 
and Metcalf 1970, Muller et al. 1994), which is the last place before they migrate to 
the bone marrow at birth (Godin and Cumano 2005). With the expression of SOX17, 
fetal HSC switch into adult HSCs (He et al. 2011). Functionally, E14.5 fetal liver 
HSCs possess the same self-renewal and multi-potency capacity as bone marrow 
HSCs (Rebel et al. 1996b, Rebel et al. 1996a, Jordan, McKearn and Lemischka 1990, 
Harrison and Astle 1997). 
  
  
13 
1.2 The development of B cells 
1.2.1 The differentiation of B cells 
B cell development starts in the fetal liver during embryonic development and 
continues in the bone marrow after birth (Whitlock and Witte 1982, Melchers 1977, 
Hardy and Hayakawa 2001, Cumano, Dieterlen-Lievre and Godin 1996, Ceredig et al. 
1999).  
 
Initially MPPs get in contact with bone marrow stromal cell via the binding of VCAM1 
on the stromal cell to VLA-4 on the progenitor cell (Oostendorp and Dormer 1997). 
This facilitates the binding of stem cell factor (SCF) on the stromal cell and c-kit on 
the stem cell as a second step (Flanagan and Leder 1990, Williams et al. 1990, 
Zsebo et al. 1990). The VLA4 and VCAM1 coupling drives MPPs to develop into 
CLPs and causes the CLPs to express the IL7 receptor. IL7 is released from stromal 
cells (Hardy and Hayakawa 2001) and initiates differentiation of pre-pro-B cells. The 
development of B cells in the bone marrow is divided to pre-pro-B cells, pro-B cells, 
pre-B cells and immature-B cells stages depending on the expression of phenotypic 
markers as well as the status of immunoglobulin locus rearrangement (Figure 1) 
(Hardy and Hayakawa 2001, John 2007, Melchers et al. 2000, Osmond, Rolink and 
Melchers 1998, Rolink et al. 1993, Rolink et al. 1999b, ten Boekel, Melchers and 
Rolink 1995) 
 
The first stage is the pre-pro-B cell (Rolink et al. 1993), which can also be called 
fraction A (Hardy and Hayakawa 2001). The cells start to express B220, which is the 
earliest B cell marker, but lack canonical B-cell markers including CD19 (Allman, Li 
and Hardy 1999, Hardy and Hayakawa 2001, Li et al. 1996, Ogawa, ten Boekel and 
Melchers 2000, ten Boekel et al. 1995) and synthesise terminal deoxynucleotidyl 
transferase (TdT) and recombination activating gene1 and 2 (Rag1 and Rag2) 
(Schatz, Oettinger and Baltimore 1989, Oettinger et al. 1990). The rearrangement of 
the immunoglobulin heavy chain locus is initiated by Rag1 and Rag2 at the diversity 
(D) and joining (J) segments (Schlissel 2003, Herzog, Reth and Jumaa 2009). 
Almost all pro-B cells have DH to JH rearranged at two alleles, suggesting that both 
alleles are accessible for variable (V) to DHJH-rearrangements (Ehlich et al. 1994, ten 
Boekel et al. 1995).  
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Figure 1 Illustration of B cell development  
B cell development is divided into pre-pro-B, pro-B, pre-B and immature-B cell stages. 
Alternatively, this process can also be divided into fraction A-F. During development, 
B cells express different surface markers: B220 is expressed on B-biased 
progenitors and all subsequent stages of B cell development. CD19 is expressed on 
pro-B cells and later stages until terminal differentiation results in plasma cells. The 
pre-BCR, comprising Ig heavy chains and λ5 and VpreB surrogate light chains, is 
present on pre-B cells. BP-1 is expressed during the entire large and small pre-B cell 
stages. The BCR on immature B cells comprises µ heavy and Ig light chains. Mature 
B cells display IgD in addition to IgM BCRs. The sequential immunoglobulin heavy 
chain and light chain rearrangement accompany the entire B cell development. HSC: 
hematopoietic stem cell, MPP: multipotent progenitor, CLP: common lymphoid 
progenitor, BCR: B cell receptor.  
 
 
The joining of a heavy chain V region segment to the D-J locus happens in pro-B 
cells (fraction B) (Hardy and Hayakawa 2001). At this stage, pro-B cells start CD19 
expression, a protein whose expression characterizes all later B lineage stages (ten 
Boekel et al. 1995, Hardy and Hayakawa 2001, Rolink et al. 1993). Cells in fraction B 
have up-regulated expression of heat stable antigen, λ5, VpreB, Igα and Igβ, which 
are part of the pre-BCR, and grow in response to IL-7 and stromal cells (Herzog et al. 
2009).  
HSC MPP Pre-Pro-B Pro-B Pre-B Pre-B Immature B  Mature B  
CD19+ 
BP-1+ 
Pre-BCR+ 
IgD+ 
IgM+ 
B220+ 
CLP 
! !
DH-JH  
 
VH-DHJH 
 
VHDHJH 
 
VHDHJH 
VL-JL 
VHDHJH 
VLJL 
VHDHJH 
VLJL 
Fr. A Fr. B Fr. C Fr. D Fr. E Fr. F 
DH-JH  
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Figure 2 Structure of the pre-B cell receptor (pre-BCR) 
Scheme of the pre-BCR complex, composed of the Ig µH chain, the surrogate light 
chains VpreB and λ5 and the signal-transducing heterodimer Igα (Mb1) / Igβ (B29).   
 
 
Following the completion of the heavy chain V to D-J rearrangement, pro-B cells 
become large pre-B cells (fraction C) (Hardy and Hayakawa 2001). These cells are 
responsive to IL-7 in the absence of stromal cells (Winkler, Melchers and Rolink 
1995). As with all immunoglobulin gene rearrangements, VDJH junctions are 
generated randomly (Tonegawa 1983). The success of VDJH rearrangements is 
controlled via pairing of the resulting µH chain with the surrogate light (SL) chain 
(Zhang, Srivastava and Lu 2004, Martensson and Ceredig 2000, ten Boekel et al. 
1995, Melchers et al. 1999). The surrogate light chain consists of two proteins: a V-
like sequence called Vpre-B and a C-like sequence called λ5 (Melchers et al. 1999, 
Sakaguchi and Melchers 1986, Kudo et al. 1987, Melchers et al. 2000). The complex 
of µH and SL chain associates with the Igα (Mb1) / Igβ (B29) heterodimer, which 
allows a pre-BCR to be deposited on the surface membrane of large pre-B cells 
(Figure 2) (Winkler et al. 1995, Brouns, de Vries and Borst 1995, Gauthier et al. 2002, 
Karasuyama, Kudo and Melchers 1990, Melchers et al. 2000, Tsubata and Reth 
1990). Once finishing the assembly of pre-BCR on the cell surface, a downstream 
signaling cascade starts, resulting in a very strong proliferation of large pre-B cells 
(Melchers et al. 2000, Rolink et al. 2000, Parker et al. 2005, Hardy and Hayakawa 
2001). The pre-BCR has two tasks: The first task is to shut down the activities and 
expression of the enzyme machinery catalyzing the rearrangements of the H-chain 
gene segments (ten Boekel, Melchers and Rolink 1998). The second task is to 
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initiate the rearrangement of the L-chain genes (Schlissel and Morrow 1994, 
Constantinescu and Schlissel 1997). 
 
After undergoing three to five rounds of cell division, large pre-B cells stop 
proliferation and differentiate into small non-dividing pre-B cells (fraction D) (Zhang et 
al. 2004, Hardy and Hayakawa 2001). At this stage, RAG proteins are expressed and 
light chain V-J joining takes place (Hardy and Hayakawa 2001, Rolink and Melchers 
2000, ten Boekel et al. 1995, Ehlich et al. 1994). Successfully rearranged κ or λ L-
chains replace VpreB / λ5 of the pre-BCR and form IgM with the H-chain (Schlissel 
and Morrow 1994, Constantinescu and Schlissel 1997, Iglesias 1991, Tsubata, 
Tsubata and Reth 1992).  
 
After lineage commitment and differentiation through pro- and pre-B cell stages in the 
bone marrow, the expression of surface IgM starts the immature B cell stage (fraction 
E). 10-20% of these immature B leave their environment and migrate to secondary 
lymphoid organs as transitional B cells, where they complete their maturation by 
differentiating into naive, follicular, or marginal zone (MZ) B cells (fraction F) (Allman 
et al. 2001, Rolink et al. 1999b, Carsetti, Kohler and Lamers 1995, Loder et al. 1999). 
Each immature B cell exclusively expresses IgM on its surface that is tested for 
reactivity against autoantigens. The binding between antigen and BCR determines 
whether the immature B cell will be selected into the peripheral B-cell repertoire. High 
affinity to multivalent (cell-associated) self antigens in the marrow lead to B cell 
apoptosis and clonal deletion. Low affinity to soluble self antigen does not kill the B 
cell, but it cannot respond to antigen with IgD expression and has a short life span, a 
state called anergic. Cells which do not bind self antigens and express normal levels 
of IgM and IgD can enter the lymphoid follicles and survive for a few weeks until they 
either encounter their specific antigen or die (Nossal and Schrader 1975, Norvell, 
Mandik and Monroe 1995, Goodnow et al. 1988, Nemazee and Burki 1989) 
 
1.2.2 Immunoglobulin recombination   
B cell development is tightly associated with immunoglobulin recombination. The 
V(D)J recombination assembles immunoglobulin and T cell receptor genes during 
lymphocyte development through a series of DNA breakage and rejoining events 
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(Schatz and Swanson 2011, Fugmann et al. 2000, Gellert 2002). The antigen-binding 
domain of the antibody consists of V (variable), D (diversity) and J (joining) segments 
(Hozumi and Tonegawa 1976). Totally, the immunoglobulin heavy chain region 
contains 44 V genes, 27 D genes and 6 J genes (Matsuda et al. 1998, Li et al. 2004). 
During the recombination process, each individual segment can be choosen 
randomly resulting in several possibilities of the junction, which is the fundamental 
reason for the diversity of antigen-receptor. This process minimizes the coding 
capacity of germline but tremendously amplify the possibility of the potential antigen-
binding specificities (Roth 2014). 
 
D-to-J joining starts with the binding of the recombinase. The recombinase consists 
of two lymphoid-specific proteins, Rag1 and Rag2, which recognize the flanking 
recombination signal sequences (RSSs). The RSSs consist of conserved heptamer 
and nonamer elements, separated by either 12 or 23 nucleotides of less conserved 
“spacer” sequence (Helmink and Sleckman 2012, Bassing et al. 2000). Once RAG 
binds to DNA, it cleaves and re-joins the DNA streams (van Gent et al. 1997). The 
RAG folds together the D and J segments to be recombined and cleaves the DNA 
exactly at the junction of the gene segment and the joining RSS motif. This cleavage 
creates a hairpin of DNA at the end of D and J segments and double strand breaks 
at the end of the RSS motif. The hairpins are opened by the activity of Artemis which 
is a crucial step of immunoglobulin rearrangment. The DNA ends are aligned via 
XRCC4, DNA ligase IV and Cernunnos, and non-templated nucleotides are randomly 
added via terminal deoxynucleotidyl transferase (TdT) to the coding end to make the 
two ends compatible for joining (Gauss and Lieber 1996). Finally, the processed 
coding ends are ligated by DNA ligase IV (van Gent and van der Burg 2007). V 
segment can join the rearranged D-J segment with the same process as D-to-J 
( Figure 3) (Schatz and Swanson 2011, Helmink and Sleckman 2012). 
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Figure 3 Immunoglobulin rearrangement of V, D and J segments to produce a 
functional antigen-receptor 
(a) Ig gene contains several V, D and J segments. Each of them is flanked by a 
recombination signal sequence. (b) RAG proteins bind randomly to different 
combination of RSS sequences guiding the DNA folding and cleavage of the internal 
region (hairpin). (c) The V(D)J rearrangement is completed resulting in functional yet 
diverse immunoglobulin genes. (d) The Ig rearrangement exists in each cell on a 
clonal basis. (Figure is taken from Slotkin and Martienssen 2007).  
 
1.2.3 Regulation of B cell development  
The development of HSCs into B cells is characterized by modulating the activity or 
the expression of lineage-determining transcription factors and cytokines (Hagman 
and Lukin 2006, Santos et al. 2011, Northrup and Allman 2008, Dahl et al. 2003). 
Several transcription factors (PU.1, Ikaros, E2A, Ebf1 and Pax5) and two cytokine 
receptors (Flk2/Flt3 and IL-7Rα) have been shown to be critical for the development 
of B cell precursors (Georgopoulos et al. 1994, Scott et al. 1994, Bain et al. 1994, 
Zhuang, Soriano and Weintraub 1994a, Nutt, Thevenin and Busslinger 1997a, 
Peschon et al. 1994, Lin and Grosschedl 1995). PU.1 and Ikaros are expressed in 
HSCs and MPPs and mutation of these genes affects multiple lineages (Yoshida et 
al. 2006, Laslo et al. 2006, Zhuang et al. 2004). In contrast, Ebf1 and Pax5 
expression is B-lineage specific (Urbanek et al. 1994, Lin and Grosschedl 1995, 
Thevenin, Nutt and Busslinger 1998, Hagman, Travis and Grosschedl 1991, Hagman 
et al. 1993) and their deletion interrupts B cell development without affecting other 
hematopoietic lineages. Flk2 and IL-7 regulate early B cell development and are 
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involved in the regulated expression of B lineage-specific transcription factors (Figure 
4) (Satterthwaite and Witte 1996). 
 
 
 
 
Figure 4 Regulation of B development 
The approximate points at which development is arrested in PU.1, Ikaros, E2A, Ebf1, 
and Pax5-deficient mice are indicted above. Deletion of PU.1 and Ikaros genes 
influences multiple lineages. The developmental arrest in E2A or Ebf1-deficient mice 
results in cells that are similar to B-biased progenitors, but which lack all Ig gene 
rearrangements. Pax5-deficient mice enter the early stage of B cell development and 
undergo D-J heavy chain rearrangement, but lack all stages beyond fraction C of B 
cell development and rearrangement of distal VH segments.  
 
 
1.2.3.1 Transcription factors regulating early B cell development  
The Ets family transcription factor PU.1 is required for the generation of both the 
innate and adaptive immune systems (Hromas et al. 1993, Scott et al. 1994, 
McKercher et al. 1996). PU.1 is expressed in hematopoietic stem cells, multipotent 
progenitors, and all differentiating cells except erythroblasts, megakaryocytes, and T 
cells (Akashi et al. 2000, Hromas et al. 1993, Anderson et al. 1999). Deletion of the 
PU.1 gene affects multiple lineages (Laslo et al. 2006). Many studies have confirmed 
the importance of PU.1 at early stages of hematopoietic development, modulating 
the chromatin structure of target genes (Iwasaki et al. 2005, Dakic et al. 2005, 
McDevit and Nikolajczyk 2006, Marecki, McCarthy and Nikolajczyk 2004, 
Nikolajczyk, Sanchez and Sen 1999, Stopka et al. 2005). For example, PU.1 has 
been discovered as an important regulator for IL-7Rα, Ebf1 and Pax5 gene 
HSC MPP Pre-pro-B Pro-B Pre-B Pre-B Immature B  Mature B  CLP 
! ! Fr. A Fr. B Fr. C Fr. D Fr. E Fr. F 
B220+ CD19+ Pre-BCR+ IL-7R!+ IgM+ IgM+IgD+ 
PU.1-/- 
Pre-BCR+ 
E2A-/- 
Ebf1-/- Ikaros-/- Pax5-/- 
Flk2+ Lin- 
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expression and immunoglobulin rearrangement (DeKoter, Lee and Singh 2002, 
McDevit et al. 2005, Marecki et al. 2004, Maitra and Atchison 2000, Nikolajczyk et al. 
1999, Torlakovic et al. 2005). Graded expression of PU.1 specifies either the myeloid 
or lymphoid fate of early hematopoietic progenitors. Low PU.1 expression induces B 
cell development, whereas high PU.1 levels suppress the B cell fate and promote 
instead macrophage differentiation (DeKoter and Singh 2000). 
 
Ikaros is a central regulator of hematopoiesis by acting downstream of PU.1 to 
promote the differentiation of a MPP into a component of the lymphocyte lineage 
(Georgopoulos et al. 1994). Ikaros is required for the development of the earliest B 
cell progenitors and at later stages for VDJ recombination and B cell receptor 
expression (Sellars, Kastner and Chan 2011). Ikaros-/- mice lack pre-pro-B cells and 
exhibit a complete block in B lymphopoiesis due to a role for Ikaros in promoting Flt3 
and/or IL-7R expression in early hematopoietic progenitors (Wang et al. 1996, 
Sitnicka et al. 2003, Nichogiannopoulou et al. 1999, Yoshida et al. 2006). Ikaros 
likely contributes to Ebf1 expression in part by activating IL-7R expression, as IL-7 
signals are required for Ebf1 transcription (Dias et al. 2005, Kikuchi et al. 2005, 
Reynaud et al. 2008). Ikaros regulates IgH rearrangement via activation of Rag 
genes (Reynaud et al. 2008). Additionally, Ikaros is thought to down-regulate 
preBCR signaling by repressing Igll1 (λ5) transcription in preB cells (Thompson et al. 
2007, Sabbattini et al. 2001). Ikaros-/- pro-B lines can be differentiated into 
macrophages when cultured with macrophage colony-stimulating factors (Reynaud 
et al. 2008). 
 
The E2A gene encodes a pair of closely related proteins, E12 and E47, which are 
generated by alternative splicing of RNA transcripts (Murre, McCaw and Baltimore 
1989). Targeted disruption of the E2A gene revealed that its products are required 
for the generation of functional B cells and for the expression of a B cell-specific 
gene program. In the absence of E2A, early B cell development is blocked at the pre-
pro B stage (Fraction A) (Zhuang et al. 1994a, Bain et al. 1994) and immunoglobulin 
gene rearrangements are undetectable (Mombaerts et al. 1992, Shinkai et al. 1992). 
Analysis of mice expressing an E2A-GFP knock-in allele has shown that E2A 
expression in B lineage cells is up regulated concomitantly with the induction of Ebf1 
and initiation of DH-JH recombination (Zhuang et al. 2004). A functional binding site 
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for E2A has been found in the Ebf1 promoter, suggesting that E2A is directly 
involved in the regulation of Ebf1 expression (Smith, Gisler and Sigvardsson 2002). 
 
 
  
 
 
Figure 5 B cell differentiation in Ebf1-deficient mice is blocked at the pre-pro-B 
cell stage 
Flow cytometric analysis of bone marrow cells from wt (left) and Ebf1-/- mice  using 
B220 and IgM expression (upper panel). In the lower panels, B220+ and CD43+ cells 
were gated and analysed for fraction A, B and C of pro-B cells using BP-1 and HSA 
expression. (Figure is taken from Lin and Grosschedl 1995).  
 
Ebf1 is a key factor in B lineage determination (Hagman and Lukin 2006). Loss of 
Ebf1 results in a block in the transition of fraction A to fraction B (Figure 5) and the 
initiation of D-J rearrangements at the IgH locus. Enforced expression of Ebf1 in 
Ebf1-deficient B220+IL-7R+ B cell progenitors reversed the arrest of B cell 
development and activated λ5, VpreB, Rag1 and Rag2, germline Iµ transcripts and 
Pax5 (Medina et al. 2004). Ebf1 activates chromatin remodelling of the mb-1 
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promoter necessary for its transcriptional activation by Pax5 (Maier et al. 2003). E2A 
and Ebf1 function synergistically to activate transcription of B lineage genes, as 
E2A/Ebf1 compound-mutant heterozygotes display a more severe defect during B 
lymphopoiesis than the single heterozygous animals (O'Riordan and Grosschedl 
1999). Consistent with this possibility, ectopic expression of E2A and Ebf1 results in 
activation of the λ5 and VpreB genes and initiation of D-JH rearrangement (Romanow 
et al. 2000). The expression of Ebf1 correlates with the expression of 565 genes 
associated with pre-BCR and BCR signaling (Mansson et al. 2004, Treiber et al. 
2010b). Ebf1 expression is compromised in PU.1-/- fetal liver hematopoietic 
progenitors, suggesting that PU.1 participates in regulation of the Ebf1 gene (Maier 
et al. 2004).  
 
In contrast to E2A and Ebf1, the transcription factor Pax5 is not required for 
specification of the B cell fate but is essential for commitment (Schebesta, Heavey 
and Busslinger 2002). Once committed to the B-lineage, B cells require Pax5 
function to maintain their B-lymphoid identity throughout their development (Nutt et al. 
2001). Pax5-/- pro-B cells express the early B-lineage genes and undergo DH-JH, and 
proximal VH- DJH gene rearrangements (Nutt et al. 1997b). Interestingly, Pax5-/- pro-
B cells exhibit extensive developmental plasticity allowing them to differentiate into all 
other hematopoietic lineages, which is suppressed upon restoration of Pax5 
expression (Nutt et al. 2001). Pax5 actively and continuously represses the 
expression of myeloid genes such as M-CSFR (macrophage colony-stimulating 
factor receptor) while inducing B-lineage genes like mb-1, CD19 and BLNK (Souabni 
et al. 2002). On this basis, E2A and Ebf1 can be regarded as primary B cell fate 
determinants and Pax5 as a B cell fate commitment factor (Singh, Medina and 
Pongubala 2005).  
 
1.2.3.2 Cytokines regulating early B cell development 
The expression of Flk2/Flt3 is the earliest regulatory event that appears to trigger B 
cell development within MPPs (Adolfsson et al. 2001). Targeted inactivation of the 
Flk2/Flt3 gene results in a severe deficiency in the generation of B lineage 
progenitors (Mackarehtschian et al. 1995). Consistent with the requirement for 
Flk2/Flt3 signaling in the development of B-lineage progenitors is the significant 
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decrease in CLPs observed in mice deficient in Flk2/Flt3 ligand (Sitnicka et al. 2002). 
The signaling pathway through which Flk2/Flt3 selectively favors the generation of B 
lineage progenitors is unknown, but in vitro data suggest that activation of this 
receptor promotes expression of the IL-7 receptor α (IL-7Rα) gene (Borge et al. 
1999). 
 
The development of pro-B cells in the bone marrow requires signaling through IL-
7Rα (Miller et al. 2002). A stromal-free culture system shows IL-7R signaling is 
sufficient to induce the differentiation of CLPs into B cells, suggesting that signaling 
through the IL-7Rα may activate the expression or modulate the activity of key 
transcriptional regulators like E2A and/or Ebf1, which are required for specification of 
the B cell fate (Sitnicka et al. 2003, Vosshenrich et al. 2003, Dias et al. 2005, Kikuchi 
et al. 2005, Kikuchi et al. 2008). IL-7-/- mice have a profound block in B cell 
generation and a reduction of CLPs in the bone marrow (Dias et al. 2005). Compared 
to their wild-type counterparts, CLPs generated in the absence of IL-7 have normal 
T/NK differentiation potential, but severely impaired B potential. Accordingly, CLPs 
from IL-7-deficient mice express lower amounts of Ebf1 and Pax5 than wild-type 
CLPs, but similar amounts of GATA-3 (Dias et al. 2005, Carvalho et al. 2001, 
Rothenberg 2002). Overall, Flk2/Flt3 and IL-7Rα induce many lineage-specific 
transcription factors in MPPs and CLPs. 
 
1.2.3.3 Early B cell development is controlled by a complex network 
of transcription factors 
Early B cell development is a highly regulated process controlled by a complex 
network. Several transcription factors and signaling pathways have been implicated 
in the regulation of this process (Kee and Murre 1998, Medina et al. 2004, Reynaud 
et al. 2008, DeKoter et al. 2002, Greenbaum and Zhuang 2002, O'Riordan and 
Grosschedl 1999, Maier et al. 2004, Sigvardsson et al. 2002, Schebesta, Pfeffer and 
Busslinger 2002, Nutt et al. 2001). Because each factor regulates multiple target 
genes, and these targets often include genes encoding one or more of the 
aforementioned transcription factors, it is often said that these proteins comprise a 
transcriptional hierarchy that serves to orchestrate early B cell development and B 
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cell specification (Nutt et al. 2001, Medina et al. 2004). A provisional model for this 
hierarchy is illustrated in Figure 6.  
 
 
 
Figure 6 Early B cell development is regulated by a complex network of 
transcription factors 
Representation of essential transcription factors responsible for the initiation of B-cell 
differentiation. An arrow represents a direct activation and a dashed arrow shows 
indirect activation; inhibition is shown using a blocked line (Mandel and Grosschedl 
2010).  
 
 
Regulation by PU.1 is dose-dependent, as low PU.1 expression induces B cell 
development, whereas high PU.1 levels suppress the B cell fate and promotes 
gtmacrophage differentiation instead (DeKoter and Singh 2000). PU.1 regulates early 
B cell development by including the expression of the IL-7 receptor α chain (IL-7Rα), 
and thus rendering lymphoid progenitors responsive to the pro-B cell differentiation 
and survival factor IL-7 (DeKoter et al. 2002). IL-7-deficient mice have no significant 
difference in the number of CLPs, but their ability to differentiate into B-lineage cells 
is greatly diminished (Dias et al. 2005). The IL-7Rα gene was identified as a direct 
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target of PU.1, since it contains a functional PU.1 binding site in its 5′ region and fails 
to be transcribed in PU.1-/- progenitors (DeKoter et al. 2002, Sitnicka et al. 2002). IL-
7 signaling activates the transcription factor STAT5, which can rescue the lymphoid 
defect in mice with a targeted mutation of the IL-7Rα gene (Goetz et al. 2004).  
 
For the B-lineage transcriptional hierarchy, Ebf1 plays a critical and dominant role 
(Medina et al. 2004). B cell development from E2A-/- progenitor cells is restored by 
introducing Ebf1 (Seet, Brumbaugh and Kee 2004).  Ebf1 also bypasses the 
requirement for Ikaros as well as IL-7Rα and PU.1 (Medina et al. 2004, Dias et al. 
2005, Kikuchi et al. 2008, Reynaud et al. 2008). In each of these cases, ectopic 
expression of Pax5 did not rescue B lymphopoiesis, indicating that Ebf1 performs 
other functions in addition to activating Pax5 expression (Dias et al. 2005, Kikuchi et 
al. 2008, Medina et al. 2004, Seet et al. 2004).  
 
 
 
 
Figure 7 Schematic overview of the distal Ebf1α and proximal Ebf1β 
promoters. 
Two different first exons of Ebf1, exon1a and exon 1b, are indicated. The distal 
Ebf1α promoter is located upstream of exon 1a and 4.4k nucleotides upstream of the 
proximal Ebf1β promoter, which is located within the first intron of Ebf1α mRNA and 
879 nucleotides upstream of the ATG-β. (Figure is taken from Roessler et al. 2007). 
 
Ebf1 is controlled through two distinct promoters, the distal α-promoter and the 
stronger proximal β-promoter (Smith et al. 2002, Roessler et al. 2007b).  
Transcription from these promoters results in the expression of two Ebf1 isoforms, 
Ebf1α and β. Due to alternative splicing, transcripts from the distal α-promoter lack 
the start codon that is used for translation of Ebf1β, generating an isoform that lacks 
14 N-terminal amino acids of the Ebf1β isoform. However, no functional difference 
between the two Ebf1 isoforms has been described so far (Figure 7) (Roessler et al. 
2007b). 
FIG. 1. The Ebf1 gene is regulated by two promoters, the distal ! and proximal " promoters. (A) Schematic overview of the distal Ebf1! and
proximal Ebf1" promoters. Two alternative first exons, exon 1a and exon 1b, are indicated. The proximal Ebf1" promoter is located within the first
intron of Ebf1! mRNA and 879 nucleotides upstream of the ATG-", which is spliced out in Ebf1! mRNA. Ebf1! mRNA and Ebf1" mRNA can
be distinguished by RT-PCR with primer pairs specific for exon 1a or exon 1b sequences. Indicated are the positions of the PCR amplicons and
of the primer used for primer extensions and S1 nuclease protection experiments. (B) Primer extension experiments show multiple bands
corresponding to potential 5# ends of Ebf1" mRNA located 879 nucleotides (nt) upstream of the ATG-". Potential transcriptional start sites are
visible only in 70/Z3 pre-B cells and in spleen, not in Ebf1-negative EL4 T cells. (C) S1 nuclease protection experiments show a similar pattern
of protected Ebf1" 5# ends as in the primer extension experiments. nt, nucleotides. (D) Alignment of the human and mouse Ebf1" promoter
transcriptional start sites. (E) Quantitative RT-PCR analysis of EL4 T cells and sorted lymphoid cells shows the upregulation of Ebf1 mRNA
during early B-cell development. HSC (Lin$ IL-7R% c-kithigh Sca-1high), CLP (Lin$ IL-7R% c-kitlow Sca-1low), pro-B cell Fr. A (B220% AA4.1%
c-kit% CD19$) and Fr. B and Fr. C according to the work of Hardy and Hayakawa (18) (Fr. B, B220% CD43% HSA% BP-1$; Fr. C, B220% CD43%
HSA% BP-1%), and marginal zone (MZ; B220% CD21high CD23low) and follicular (FO; B220% CD21low CD23high) B cells have been sorted by
FACS to more than 98% purity. Ebf1 mRNA levels were normalized to "-actin, and the expression level of HSC was set to 1. (F) Quantitative
RT-PCR analysis of endogenous levels of Ebf1! and Ebf1" mRNA. The ratio of Ebf1" to Ebf1! mRNA is displayed. Ebf1" mRNA is
predominantly expressed in all analyzed cell types, and the ratio increases during pro-B-cell development, with the highest ratio being in fraction
C pre-B cells.
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The distinct proteins activate the Igll1 promoter in vitro equivalently, suggesting that 
the alternative proteins maybe a consequence of the need for differential promoter 
regulation rather than distinct biological functions. The Ebf1α promoter is regulated 
by E2A and IL7 (Roessler et al. 2007b). Because STAT5 is activated by IL-7R 
signaling, this finding provides a possible explanation for the dependence of initial 
Ebf1 expression on both E2A and IL-7R (Dias et al. 2005, Kikuchi et al. 2005, Seet et 
al. 2004). The Ebf1β promoter is regulated via Ets1, PU.1 and Pax5 (Roessler et al. 
2007b). Ebf1 regulates its own expression directly through induction of the Ebf1α 
promoter and indirectly through up-regulation of Pax5, suggesting an auto-regulatory 
function for Ebf1. Compared to wild-type pro-B cells, Pax5-/- pro-B cells have reduced 
Ebf1 mRNA resulting predominantly from decreased transcription from the Ebf1β 
promoter (Roessler et al. 2007b). This feedback regulation by Pax5 on Ebf1 could 
function to amplify B cell-specific gene expression and solidify commitment to the B 
cell pathway (Figure 8). 
 
  
   
Figure 8 Representation of the complex regulatory network at the two Ebf1 
promoters 
The two promoters of Ebf1 along with the known regulators are indicated. The gene 
product of the two promoters differs by 14 amino acids at the N terminus. An arrow 
represents a direct activation and a dashed arrow shows indirect activation, inhibition 
is depicted using a blocked line. (Figure is taken from Roessler et al. 2007). 
 
The transcription factors E2A and Ebf1 are required at a similar step in early B cell 
differentiation (Schlissel, Voronova and Baltimore 1991, Choi et al. 1996, Kee and 
Murre 1998). B cell development is impaired at the pro-B cell stage in E2A+/- Ebf1+/- 
mice, because of reduced expression of multiple B-lymphoid genes including Rag1 
subnuclear position (36, 57). We therefore analyzed the large-
scale chromatin organization of the Ebf1 locus in Pax5!/! and
wild-type cells by 2D-FISH analysis. We observed that th Ebf1
locus was more often positioned towards the periphery of the
nucleus in Pax5!/! cells than in wild-type cells (Fig. 8A and B).
The nuclear periphery has previously been associated with
later replication times and transcriptional inactivity (23, 34, 39,
56, 61). Our observation that in the absence of Pax5, Ebf1
replicates later and locates towards the nuclear periphery is
consistent with our finding that Pax5 upregulates transcription
from the Ebf1 promoter and suggests that Pax5 regulation of
Ebf1 involves large-scale chromatin organization changes at
the locus and nuclear repositioning.
DISCUSSION
Ebf1 is a key regulator of early -cell differentiation that
participates in the specification of the cell lineage. Ebf1 is
expressed as early as in CLPs, although the functional activity
of EBF1 is required for the generation of pro-B cells (fraction
B cells) that undergo the rearrangement of immunoglobulin
heavy chain genes (25). Moreover, retroviral transduction of
FIG. 8. Fluorescence in situ hybridization shows differential Ebf1 locus positioning in Pax5-deficient compared to wild-type (wt) pro-B cells.
(A) Representative images of 2D-FISH analysis of Pax5-deficient and wild-type pro-B cells. (B) Analysis of the nuclear position of the Ebf1 locus
shows that the Ebf1 locus is more often detected at the periphery of the nucleus in Pax5-deficient than in wild-type pro-B cells. (C) A complex
regulatory network regulates the expression of the two Ebf1 promoters.
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and Rag2 (O'Riordan and Grosschedl 1999).  E2A induces Ebf1 in a macrophage 
line and strongly synergizes with Ebf1 to regulate the expression of the surrogate 
light chain (λ5, VpreB) and signaling components (Igα, Igβ) of the pre-BCR (Kee and 
Murre 1998, Sigvardsson, O'Riordan and Grosschedl 1997, Sigvardsson 2000, 
Sigvardsson et al. 2002, Gisler and Sigvardsson 2002). The promoters of both the λ5 
and VpreB genes contain functional binding sites for Ebf1 and E2A (Kudo and 
Melchers 1987, Sigvardsson et al. 1997).  
 
Further evidence shows that E2A acts upstream of Ebf1 in the genetic hierarchy of 
early B cell development (Smith et al. 2002). Pre-pro B cells express almost normal 
levels of E2A mRNA in Ebf1-/- mice, whereas Ebf1 transcripts appear to be reduced 
in E2A-/- bone marrow cells (Bain et al. 1997, Lin and Grosschedl 1995). Ectopic 
expression of E2A could activate endogenous Ebf1 gene in contrast to Ebf1, which is 
unable to induce E2A transcription (Kee and Murre 1998).  
 
Pax5 represses the expression of myeloid genes such as M-CSFR and T-lineage 
genes such as Notch1, which actively inhibit B cell generation providing a molecular 
explanation for the lineage plasticity of the Pax5-/- pro-B cells (Souabni et al. 2002, 
Tagoh et al. 2006, Nutt et al. 1999). Pax5 is a direct target of Ebf1 and can regulate 
the expression of Ebf1 via the positive feedback loop involving the βEbf1 promoter 
(Roessler et al. 2007b, Decker et al. 2009). The activation of IgH-VDJ rearrangement 
initiates a feed forward loop between Pax5 and Ebf1 and eliminates the potential for 
alternative cell fate (Decker et al. 2009). The target genes of Ebf1 are detectable in 
Pax5-/- pro-B cells, showing that Pax5 functions downstream of Ebf1 in the control of 
B cell development (Nutt et al. 1997b). In contrast, Pax5 expression is reduced in 
pro-B cells of compound heterozygous E2A+/-Ebf1+/- mice and can be induced by 
ectopic expression of E2A or Ebf1 in a 70Z/3 macrophage cell line (Kee and Murre 
1998, O'Riordan and Grosschedl 1999).  
 
1.3 Early B cell factor (Ebf1) 
Ebf1 is a helix- loop-helix (HLH) transcription factor belonging to a protein family 
consisting of 4 highly conserved members. It was discovered due to its binding to a 
functionally important palindromic site within the early B cell-specific CD79a promoter 
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(Hagman et al. 1993, Feldhaus et al. 1992). The CD79a promoter drives expression 
of Ig-α, a transmembrane protein that is essential for assembly and signaling function 
of the pre-B cell receptor (pre-BCR) and the BCR on the B cell plasma membrane 
(Hombach et al. 1990, Campbell et al. 1991, Gold et al. 1991).  
 
1.3.1 Protein structure of Ebf1 
The major isoform of Ebf1 consists of 591 amino acids, which includes an N-terminal 
DNA-binding domain (DBD) and an Ig-like/plexins/transcription factors (IPT) domain, 
a helix-loop-helix (HLH) dimerization domain, and a C-terminal transactivation 
domain (Hagman and Lukin 2005, Boller and Grosschedl 2014, Treiber et al. 2010a). 
Ebf1 binds its palindromic DNA-binding motif 5’-TCCCNNGGGA as a homo-dimer of 
two 65 kDa subunits with high affinity (Figure 9) (Travis et al. 1993).  
 
The DBD of Ebf1 folds into a β-sandwich consisting of a four- and five-stranded anti-
parallel β-sheet (Liberg, Sigvardsson and Akerblad 2002). Ebf1 keeps contacts with 
the major and minor grooves of the palindromic DNA site through three distinct motifs: 
a central module, the zinc knuckle and the GH loop. The major contribution to 
sequence specific DNA binding is provided by the central module comprising small 
β-sheets and loops which recognize bases within the major groove of one half-site of 
the palindromic binding site. The zinc knuckle establishes contacts with the minor 
groove of the other half- site (Treiber et al. 2010a). Biochemical analysis 
demonstrates a zinc-coordination motif, H-X3-C- X2-C-X5-C, located between amino 
acids 157 and 170 of Ebf1 (Treiber et al. 2010a, Fields et al. 2008). An expanded 
view of the zinc knuckle highlights the histidine and three cystine residues that 
coordinate the zinc ion required for DNA binding (Treiber et al. 2010a). Because of 
its difference to the canonical zinc finger structure, this atypical zinc finger motif was 
named ‘zinc knuckle’ or ‘COE motif’ (Hagman and Lukin 2005). In addition, the GH 
loop protrudes into the minor groove outside of the conserved recognition motif, 
which is important for DNA-binding affinity but does not appear to contribute to the 
specificity of sequence recognition (Treiber et al. 2010a). 
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Figure 9 Structure of Ebf1  
The domains of Ebf1 are labeled and colored consistently throughout. A schematic 
representation of the domains in Ebf11–591 includes the DNA-binding domain (DBD) 
with a unique zinc knuckle involving a central motif (red) and its coordinating motif 
(purple). The DBD (orange), TIG/IPT and HLH domains all participate in Ebf1 
dimerization. The carboxyl terminus includes the Ser/Thr/ Pro-rich transactivation 
domain (light grey). The amino acids demarcating each domain are numbered (upper 
part). The structure of an Ebf135–412 dimer interacts with DNA (grey) via the zinc ions 
shows as red spheres. The perspective is parallel to the helical axis of the DNA 
molecule. The visible portion of the HLH domain, the TIG/IPT domain, the DBD 
domains and the zinc knuckle motifs are indicated (red; lower part). (Figure is taken 
from Boller and Grosschedl 2014).  
 
 
The Ebf1 dimer assembles a unique symmetric clamp extending across both half-
sites of the palindrome. This configuration explains the strict requirement for a two-
nucleotide spacer between the half-sites recognized by Ebf1, as has been noticed in 
mutation analyses (Travis et al. 1993). The mutagenesis of contact residues of Ebf1 
grooves of DNA (22). Recent determination of the crystal
structures of EBF1 and an EBF1:DNA complex clarified the
three-dimensional architecture of the DBD and elucidated
the interaction between EBF and DNA at atomic resolution
(31, 32) (Fig. 2). The DBD folds into a b-sandwich, which
consists of a four- and a five-stranded anti-parallel b-sheet.
DNA interaction is mediated by three distinct DNA interac-
tion modules, the GH loop, a central module, and the zinc
knuckle, that extend from the b-sandwich (31). Most of the
sequence specificity of DNA binding by EBF1 is provided by
the central module. It is composed of small b-sheets and
loops that reach deep into the major groove, contacting spe-
cific nucleotides of one half-site of the palindromic binding
sequence. The zinc knuckle, which consists of short a-heli-
ces, contacts the other half-site in the minor groove. The
large GH loop protrudes into the minor groove outside of
the binding motif. Although the GH loop is important for
DNA-binding affinity, it does not appear to contribute to
the specificity of sequence recognition (31). The crystal
structure confirmed the binding of DNA by a dimer of EBF1
(22). Interestingly, the two monomers of EBF1 form a sym-
metric clamp over the entire binding motif. In this struc-
ture, each monomer contacts both half-sites of the
palindromic consensus sequence. Although EBF1 shows no
amino acid sequence similarity with other families of DNA-
binding proteins, the three-dimensional architecture of the
EBF1 DBD resembles the N-terminal half of the Rel-homol-
ogy domain (RHD), which is found in NF-jB and NFAT
(31, 32).
The DBD is followed by an IPT domain that extends from
aa 262 to 345 (33). The RRARR motif located between the
DBD and the IPT domain was proposed as a putative nuclear
localization signal (NLS) (25). As predicted by sequence
comparison and underlined by the crystal structure, the IPT
domain adopts an immunoglobulin-like fold. It resembles
the C-terminal half of the RHD. The structural similarities of
Fig. 2. Structure of EBF1. A schematic presentation of the domain structure of murine EBF1 [modified after Hagman and Lukin (38)] and the
crystal structure of a DNA-bound EBF1 dimer that lacks the C-terminal transactivation domain [modified after Treiber et al. (31) using PDB file
3MLP are depicted]. The structure was modeled using Discovery Studio 3.5 Visualizer, Accelrys Inc., San Diego, CA. The DNA-binding domain
(DBD) is colored in orange, the IPT domain in green, the helix-loop-helix (HLH) dimerization domain in blue and the C-terminal transactivation
domain (TAD) in light gray. The DNA interacting modules within the DBD are colored in red (central motif), purple (zinc coordinating motif)
and turquoise (GH loop). Zinc ions are represented by red spheres. The border amino acids of each domain are indicated in the schematic.
© 2014 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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confirmed their importance for DNA binding (Fields et al. 2008, Siponen et al. 2010, 
Treiber et al. 2010a).  
 
The C-terminus of the DBD is followed by an IPT domain folding in an 
immunoglobulin-like structure that extends from amino acid 262 to 353 (Bork et al. 
1999). Although the IPT domain participates in the dimerization of Ebf1, the major 
part of the contact area is contributed by the HLH domains, which are necessary for 
dimerization in the absence of DNA (Hagman et al. 1995). A single HLH domain 
consists of two amphipathic helices (Hagman et al. 1993, Wang, Tsai and Reed 1997, 
Wang, Betz and Reed 2002), and four helices form a helix bundle of dimerized HLH 
domains (Ma et al. 1994, Hagman and Lukin 2005, Treiber et al. 2010a). The second 
helix is duplicated in vertebrates, resulting in a helix-loop-helix-loop-helix motif, for 
which no additional electron density has been detected arguing against a compact 
inclusion but raising the possibility of interaction with other proteins (Treiber et al. 
2010a, Siponen et al. 2010). 
 
1.3.2 Molecular mechanism of Ebf1 function 
Within the hematopoietic system, Ebf1 is expressed exclusively in B cells from the 
earliest step on, and is functionally required for early B cell development targeting 
around 3000 genes, which are strongly associated with B cell function and BCR 
signaling (Mandel and Grosschedl 2010, Nutt and Kee 2007, Zandi, Bryder and 
Sigvardsson 2010, Treiber et al. 2010b). The 3000 target genes can be divided into 
three groups: activated, repressed and poised genes, which are bound by Ebf1 in 
early B-cell stages but expression is detected only at later stages of the B lineage 
(Treiber et al. 2010b). 
 
Independent of transcriptional activation or repression, ectopic expression of Ebf1 in 
a pre-T cell line results in the modification of histone 3 at lysine 4 (H3K4me2) of B 
cell specific Ebf1 targets (Treiber et al. 2010b). During B cell development, the 
CD79a promoter is activated by the collaboration of Ebf1, Runx1, E2A and Pax5 
(Maier et al. 2004, Sigvardsson et al. 2002, Maier et al. 2003). In studies of the Ebf1 
target gene CD79a, Ebf1 has been shown to contribute to epigenetic regulation of 
the promoter through CpG demethylation and nucleosomal remodelling. These 
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modifications increase local chromatin accessibility, but they do not lead to 
transcription in the absence of other transcription factors (Maier et al. 2004). Ebf1 
function is also associated with the chromatin-remodeling complexes SWI/SNF and 
Mi-2/NuRD. Ebf1-mediated induction of chromatin accessibility at the Cd79a 
promoter is dependent on the SWI/SNF complex, whereas the Mi-2/NuRD complex 
is involved in chromatin compaction and DNA hypermethylation at the Cd79a 
promoter (Gao et al. 2009). The Ebf1-activated targets CD79a, Gfra2, and Pax5 gain 
H3K4 methylation and H3 acetylation marks upon the transition to the pro-B stage, 
correlating with their transcriptional activation (Treiber et al. 2010b). Although some  
targets bound by Ebf1 specifically in mature B cells show H3K4me2 modifications 
already in pro-B cells, H3K4 di-methylation with Ebf1 occupancy is mainly detected in 
mature B cells (Gyory et al. 2012).  
 
1.4 Post-translational modification  
The human genome comprises 20,000 to 25,000 genes while the proteome is over 1 
million, indicating that single genes encode multiple proteins (Jensen 2004). The 
complexity is further increased from the level of the genome to the proteome by post-
translational modifications (PTMs), which are known to be essential mechanisms 
used by eukaryotic cells to diversify their protein functions and dynamically 
coordinate their signaling networks (Wang, Peterson and Loring 2014).  
 
PTMs are chemical modifications that play a key role in functional proteomics, 
because they regulate activity, localization and interaction of proteins with other 
cellular molecules such as proteins, nucleic acids, lipids, and cofactors (Jensen 
2004). Over 200 types of PTMs occur by enzymatic activity (Walsh, Garneau-
Tsodikova and Howard-Jones 2006). These enzymes include kinases, 
phosphatases, transferases and ligases, which add or remove functional groups, 
proteins, lipids or sugars to or from amino acid side chains, and proteases, which 
cleave peptide bonds to remove specific sequences or regulatory subunits. Many 
proteins can also modify themselves using autocatalytic domains, such as 
autokinase and autoprotolytic domains (Krishna and Wold 1993). 
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Post-translational modifications are changes made to a polypeptide or protein any 
time after translation. For example, many proteins are modified shortly after 
translation to mediate proper protein folding or stability or to direct the nascent 
protein to distinct cellular compartments (Grotenbreg and Ploegh 2007). Other 
modifications occur after folding and localization in order to activate or inactivate 
catalytic activity or to influence the biological activity of the protein (Geiss-Friedlander 
and Melchior 2007).  
 
The most common types of PTMs studied in protein research today are focused on 
phosphorylation, glycosylation, ubiquitination, acetylation and methylation. PTMs can 
be experimentally detected by a variety of techniques, including mass spectrometry, 
eastern blot and western blot (Gianazza, Crawford and Miller 2007). 
 
1.4.1 Phosphorylation  
Phosphorylation affects a large number of proteins in eukaryotic cells. 
Phosphorylation is associated with protein activity and plays a key role in protein 
function regulation. The change of conformation can alter the catalytic activity of a 
protein, which means the protein can be activated or inactivated. Another effect of 
phosphorylation is to recruit other proteins, which contain a domain recognizing and 
binding to phosphomotifs. For example, MH2 and WW domains can recognize and 
bind to phosphoserine; SH2 and PTB domains can recognize and bind to 
phosphotyrosine; FHA domains can recognize and bind to phosphothreonine. Thus 
phosphorylation can regulate protein interactions resulting in signal transduction via 
downstream effector proteins (Yaffe 2002). This intracellular signal transduction is 
involved in the mediation of cell cycle progression, differentiation, development, 
peptide hormone response, adaptation and transformation (Hubbard and Cohen 
1993, Pawson and Scott 1997, Hunter 2000, Toska et al. 2002). 
 
Phosphorylation only occurs at the side chain of serine, threonine and tyrosine. The 
amino acids have a hydroxyl group that attacks the terminal phosphate group (PO42-) 
on a universal phosphor donor adenosine triphosphate (ATP), resulting in the 
transfer of the phosphate group to the amino acid side chain. This transfer is 
facilitated by magnesium (Mg2+). Protein phosphorylation is a reversible PTM that is 
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mediated via kinases or phosphatases (Toska et al. 2002). The reversibility of protein 
phosphorylation also contributes to signal transduction allowing cells to respond to 
intracellular or extracellular stimuli (Johnson and Lewis 2001). In many cases, 
receptors activate downstream kinases, which then phosphorylate and activate their 
cognate downstream substrates, including additional kinases, until the specific 
response is achieved.  
 
Substrates for kinase activity are diverse and include lipids, carbohydrates, 
nucleotides and proteins. An important co-substrate for almost all protein kinase is 
ATP, which is an ideal structure for the transfer of phosphate groups for nucleotidyl-, 
pyrophosphoryl- or phosphoryltransfer, respectively (Maltese 1990). Protein kinases 
are categorized into subfamilies that catalyse distinct domains. Approximately 80% of 
the mammalian kinome comprises serine and threonine kinases, and over 90% of 
the phosphoproteome consists of pS and pT. Indeed, the relative abundance ratio of 
pS: pT: pY in a cell is 1800:200:1 (Mann et al. 2002). Specificity is achieved via 
sequences flanking the consensus sites (Pawson and Nash 2003). Based on the 
consensus sequence, kinases not only phosphorylate a single protein but multiple 
substrates if the kinase-specific consensus sequences are available (Maltese 1990). 
 
1.4.2 Post translational modification of Ebf1 
Ebf1 was first described in 1991 since when the biological and biochemical function 
of Ebf1 have been studied (Hagman et al. 1991, Feldhaus et al. 1992). Conditional 
deletion of Ebf1 shows that it fulfills different roles during B cell development: 
activation, repression and poising of different target genes. Since these processes 
differ strongly, Ebf1 very likely needs to have different interaction partners and likely 
differs itself in these processes.  
 
Post-translational modifications can significantly regulate activation, localization and 
interaction with other proteins, and all of these processes potentially affect the role of 
Ebf1 during B cell differentiation. Mass spectrometry is a classic method for the 
identification of PTM and amino acids affected thereby (Jensen 2004, Jiang, den 
Hertog and Hunter 2000). To isolated Ebf1 protein, Ebf1-flag was over expressed in 
HEK293T and 18-81 TK+ cell, and immunoprecipitated using anti-flag antibody 
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(Dr.Gerald Burgstaller, HMGU Munich). The purified Ebf1 protein was analysed via 
mass spectrometry under conditions allowing the identification of PTM (Dr. Hakan 
Sarioglu, HMGU Munich) 
 
 
 
Figure 10 Identification of post-translational modifications of Ebf1 
A: Western blot analysis of immunoprecipitated Ebf1-flag from HEK293T (left) and 
18-81 TK+ cells, which ectopically express Ebf1-flag via transient transfection. 
Western blot and immunoprecipitation (IP) were performed using an anti-flag 
antibody. IP is a control to show the endogenous Ebf1 expression in 18-81 TK+ cells. 
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Beads only is a negative control. B: Silver staining of immunoprecipitated proteins 
from HEK293T (left) and 18-81 TK+cells.  The precipitated proteins are isolated via a 
denaturing SDS-polyacrylamide gel. Ebf1 protein is indicated by an arrow, the protein 
size is approximately 72 kDa. Two independent IPs are shown (IP1, IP2). C: 
Phosphorylated Ebf1-S13 and S14 are identified by mass spectrometry. The 
phosphorylated Ebf1-S13 and S14 were spiked at equimolar level. D: The N-terminal 
amino acid sequence of βEbf1. S13 and S14 are marked in red to indicate the sites of 
phosphorylation. The methionine (M) located next to S14 is the starting of αEbf1. 
DBD: DNA binding domain, TIG: immunoglobulin-like plexin. HLH: helix loop helix, 
TAD: transactivation domain.  
 
 
 
Recording coverage of more than 60% of total amino acids of Ebf1, three sites for 
phosphorylation were identified, two of which are studied here: Serines located at 
position 13 and 14 of Ebf1 (Ebf1-S13, Ebf1-S14). The phosphorylation of Ebf1 at S13 
and -S14 are only detectable in pre-B cell line cells (18-81 TK+), but not in human 
kidney cells (HEK293T) indicating a certain cell type specificity. As αEbf1 lacks the 
first 14 amino acids, phosphorylated Ebf1-S13 and -S14 are only part of in βEbf1. This 
phosphorylation of Ebf1-S13 and -S14 might regulate its interaction with other proteins, 
thereby allowing a differential influence on early B cell development.   
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2 Aim of Study 
 
Early B cell differentiation is regulated via a complex transcriptional network. Ebf1 is 
a central part of it, regulating around 3000 target genes associated with B cell 
function. Among these target genes, Ebf1 plays diverse roles to activate, repress or 
poise gene expression. Post-translational modification represents a potential 
explanation for these diverse roles. Specifically, phosphorylation of Ebf1 might 
contribute to the diverse functions of Ebf1 during B cell development.  
 
The hypothesis of this study is that phosphorylation of Ebf1 at S13 and S14 plays a 
role in B cell development, and the aim of this study is to clarify the role of 
phosphorylation on Ebf1 S13 and S14 in early B cell development.  
 
This study confirms the post-translational modification of endogenous Ebf1 via 
monoclonal antibodies, which only recognized the phosphorylated Ebf1-S13 and S14. 
We investigate the role of phosphorylated Ebf1-S13 and S14 in primary B cells. As a 
transcription factor, the molecular mechanism of Ebf1 is to bind to DNA and regulate 
the expression of target genes. Therefore, we analyse the biological and biochemical 
function of phosphorylated Ebf1-S13 and S14 in B cell development. 
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3 Material and Methods  
3.1 Material 
3.1.1 Instruments 
Manufacturers Device 
Peqlab Biotechnologie GmbH Agarose Gel Chambers 
CP2245; Sartorius AG Accuracy Weighing Machine 
B6120, Heraeus; Thermo 
Scientific 
Bacterial Incubator 
Trans-Blot Semi-Dry Transfer 
Cell; Bio-Rad 
Blotting Chamber 
CASY TTC, Innovatis Cell Counter 
Rotina 38R; Hettich 
Micro 200R; Hettich 
Rotanta 460R; Hettich 
Eppendorf centrifuge 5424; 
Eppendorf 
Centrifuges 
CB150; Binder CO2-Incubator 
TYPON Optimax; Raymed 
Imaging AG 
Film Developer 
Gene Pulser®; Bio-Rad Electroporation System 
FACSCaliburTM Flow Cytometer; 
BD Biosciences 
FACSCantoTM Flow Cytometer; 
BD Biosciences 
FACSAriaTMIII Flow Cytometer; 
BD Biosciences 
Flow Cytometry 
Bio-Rad Gel Dryer 
Thermomixer Compact; 
Eppendorf 
Heating Block 
AF 100; Scotsman® Ice Machine 
Karl Hecht GmbH&Ko KG Improved Counting Chamber 
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Herasafe KS12; Thermo Electron 
Corporation 
Laminar Flow 
LightCycle® 480 II; Roche Light Cycler 
Microplate Luminometer Orion II; 
Berthold Detection Systems 
Luminometer 
RCT basic safety control (IKA) Magnet Stirrer 
Panasonic Microwave 
Axiovert25; Zeiss Microscope 
TV21; CTI GmbH Native PAGE-Apparatus 
DNA Engine®; Bio-Rad PCR Machine 
Mini Trans-Blot® Cell; Bio-Rad SDS-PAGE Chamber 
BioPhotometer; Eppendorf Spectrophotometer 
DNA-Engine®; Bio-Rad PCR Machine 
Photometer Bio 6131; Eppendorf Photometer 
Gilson Pipettes 
763 Multi Calimolic; Knick pH-Meter 
0.2 ml PCR-Reaction tube; 
Biozym Diagnostik 
15 ml, 50 ml; Falcon 
0.5 ml, 1.5 ml, 2 ml, Eppendorf 
Reaction Vessels 
Polymax 1040; Heidolph Shakers 
Light Cycler 480II; Roche Thermo Cycler 
Transilluminator TL33; 
HEROLAB GmbH 
UV-Transilluminator 
BVC 21; Vacuubrand Vacuum Pump 
Vortex Genius (IKA) Vortexer 
PowerPack300X; 
BioRad 
Voltage Source 
Sub6; 
Grant 
Waterbath 
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3.1.2 Consumables  
Manufacturers Products 
ART® Molecular BioProducts  Pipette Tips 
Becton Dickinson (BD) GmbH Round-Bottom Tube: 5 ml 
Round-Bottom Tube with Strainer Cap: 5 ml 
Conical Tubes: 15 ml, 50 ml 
Luer-LokTM Syringe: 20 ml  
Cell Culture Flasks: 75 cm2, 175cm2 
Cell Culture Plates: various 
Tissues Culture Dish: 10 cm2 
Cell Strainer: 70 µm Nylon, 100 µm Nylon 
BioRad Gene Pulser® Cuvettes 
Biozym Biagnostik GmbH PCR Tube: 0.2 ml 
Brand Disposable Cuvettes 
Braun Sterican® Cannulas 0.4 x 20 mm, 27G x 3/4’’, 
Size 20 
CEA GmbH Medical X-Ray Screen Film Blue Sensitive 
Corning Incorporated Sterile Disposable Pipettes 
Eppendorf Cuvette® 220-16 mm; Test Tube: 1.5 ml, 2 ml 
Gilson D10, D200, D1000 Diamond® Tower PackTM 
tips 
Millipore Syringe Filter: 0.22 µm 
Nunc GmbH Cryo TubeTM Vials 
Pharmacia Sephadex® G-50 Column 
Protran Nitrocellulose Membrane 
Roche Diagnostics LightCycler® 480 Multiwell Plate 96 
LightCycle® 480 Sealing Foil 
Schott, Braun Glass Ware 
Sigma Kodak BioMax MS Film 
USA scientific LumitracTM 2000 96W Microplate 
Whatman GmbH Gel-Blotting-Paper: 0.34 mm; 1.2mm 
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3.1.3 Chemicals and Enzymes 
Manufactures Products 
Applichem Propidium Iodide 
Applied Biosystems EmeraldTM Enhancer; 
Galacton-Plus® Chemiluminescent Substrate 
for β-Galactosidase 
Bayer Ciprobay® 400 
Biochrom AG Fetal calf serum (FCS) 
Biolab Products CRYSTAL agarose 
Fermentas dNTPs (100 mM) 
Glycogen 
Gibco BRL Dulbecco’s Modified Eagle Medium (DMEM);  
Dulbecco’s Phosphate Buffered Saline (PBS);  
L-Glutamine, 200 mM, 100 x; OptiMEM®; 
Penicillin/Strptomycin (10.000 U/ml & 10.000 
µg/ml);  
Polyethylenimin (PEI);  
RPMI 1640; Sodium Pyruvate, 100 mM; 
Trypsin-EDTA, 0.05% 
Hartmann Analytic 32P-Alpha-dCTP (3000 Ci/mol) 
Invitrogen Life Technologies 5 x First Strand Buffer; 
Dithiothreitol (DTT); 
Oligo (dT) 12-18 Primer (0.5 µg/µl); 
SuperScript® II Reverse Transcriptase (200 
U/µl) 
New England Biolabs 1 x NEBuffer 2 & 3 
Calf Intestinal Alkline Phophatase  
(10 U/µl) 
PAA Laboratories Bovine Serum Albumin (BSA) 
PAN Biotech Fetal calf serum (FCS) 
Peqlab peqGOLD TriFastTM 
Promega RNasin® (40 U/µl) 
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R & D Systems  Recombinant Mouse IL-3; 
Recombinant Mouse IL-6; 
Recombinant Mouse SCF 
Roche Diagnostics Acetyl-Coenzyme A; 
Aprotinin; 
ATP disodium salt; 
Complete, Mini, EDTA-free Tablet; 
D(-)-Luciferin; 
Klenow Fragment, 2 U/µl; 
Leupeptin; 
LightCycler® 480 SYBR Green I Master; 
Phosphatase Inhibitor Cocktail Tablet; 
PMSF 
Roth Ammonium Persulfate ( Knapstein et al.); 
Ampicillin; 
Dimethylsulfoxid (DMSO); EDTA; Glycerin; 
Glycin; Ponceau S; Proteinase K; 
Rotiphorese® Gel 40 (Acrylamid/Bisacrylamid 
29:1); N,N,N,N-Tetramethylethylendiamin 
(TEMED);Tris; Powdered milk; Tween® 20 
Sigma 2-Mercaptoethanol; Chloroform; Luminol 
Sodium Salt; NonidetTM P40 Substitute; 
ρ-Coumaric Acid; Polybren; 
Poly (deoxyinosinic-deoxycytidylic) Acid 
Sodium Salt (Poly (dI-dC)) 
Solis BioDyne 1 x FirePol Puffer B 
FIREPol® DNA Polymerase (5 U/µl) 
Thermo Scientific 
 
BamHI (10 U/µl); 10 x BamHI Buffer;  
BgIII (10 U/µl); 10 x B Buffer; Spel (10 U/µl); 10 
x 0 Buffer; 10 mM dNTP; EcoRI (10 U/µl); 5 x 
Phusion HF Buffer; Phusion DNA Polymerase; 
pJET1.2/blunt Cloning Vector (50 ng/µl); 2x 
Reaction Buffer; Stul (10 U/µl); T4 DNA Ligase 
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3.1.4 Kits 
Manufactures Kits 
LightCycler® 480 SYBR Green I Master Roche 
Pierce® BCA Protein Assay Reagent Thermo Scientific 
QIAGEN® Plasmid Midi/Maxi Kit QIAGEN GmbH 
Quik Change®, Site-Directed 
Mutagenesis Kit 
Stratagene 
Wizard® SV Gel and PCR Clean-Up 
System 
Promega 
 
3.1.5 Size Markers 
Manufactures Products 
GeneRulerTM 100 bp Plus DNA Ladder Fermentas 
PageRulerTM Prestained Protein Ladder Fermentas 
 
3.1.6 Antibodies 
3.1.6.1 Peptide anti-Ebf1-S13 (p), 14 (p) antibodies 
The peptide sequence used to generate Anti-Ebf1-S13 (p) and –Ebf1-S13 (p) S14 (p) 
Antibodies is: SIQRSGS(p)S(p)MKEEPC (Ebf1: amino acids 7-19). The C-terminal 
cysteine was added. Dr E.Kremmer and colleagues, HMGU Munich, generated the 
antibodies.  
 
 
 
 
 
 
 
 
 
 
(5 U/µl); XhoI (10 U/µl);  
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3.1.6.2 Antibodies for western blot and electrophoretic mobility 
shift assay (EMSA) 
p: phosphor specific antibody; np: non-phosphor specific antibody 
Undiluted antibodies are derived from hybridoma supernatant.   
 
 
 
 
 
Antibody Clone Host 
Species 
Manufactures Dilution 
Anti-β-Actin 
 
AC-74 
Monoclonal 
Mouse Sigma 1:10000 
 
Anti-Ebf1-S13(p) 
 
14H6, Isotype 
IgGG1, 
Monoclonal 
Rat E.Kremmer, 1:1 
Anti-Ebf1-S13 (p) S14(p) 
 
1C4, Isotype 
IgGG1, 
Monoclonal 
Rat E.Kremmer 
HMGU 
1:1 
Anti-Ebf1-S13 (np) S14(np) 
 
1E12, Isotype 
IgG2c, 
Monoclonal 
Rat E.Kremmer 
HMGU 
1:1 
Anti-FLAG® M2 
 
Monoclonal Mouse Sigma 1:10000 
Anti-Pan-Ebf1 
 
5E6, Isotype 
IgG2a, 
Monoclonal 
Rat E.Kremmer, 
HMGU 
1:1 
Anti-Mouse IgG 
 
Peroxidase 
Polyclonal 
Goat Sigma 1:5000 
Anti-Rat IgG-IgM Peroxidase- 
Polyclonal 
Goat Jackson 
Immuno 
Research 
1:5000 
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3.1.6.3 Antibodies for flow cytometry 
Antibody Clone Host 
Species 
Manufactures Dilution 
Anti-B220-FITC RA3-6B2 Mouse BD Diosciences 1:500 
Anti-BP-1-Biotin 6C3 Mouse eBioscience 1:500 
Anti-CD19-Biotin 1D3 Mouse eBioscience 1:500 
Anti-CD24-PE 30F1 Mouse eBioscience 1:2500 
Anti-CD43-APC S7 Mouse eBioscience 1:500 
Anti-CD45.2-APC 104 Mouse eBioscience 1:500 
Anti-IgD-Biotin 11-26 Mouse eBioscience 1:500 
Anti-IgM-APC II/41 Mouse eBioscience 1:250 
Streptavidin-PE   eBioscience 1:500 
Streptavidin-PerCP-
Cy5.5 
  eBioscience 1:500 
 
3.1.7 Oligonucleotides 
All oligonucleotides listed are purchased from Metabion Company. 
 
3.1.7.1 Oligonucleotides for quantitative PCR 
Oligonucleotide Sequence 5’→ 3’ Amplification Product 
(bp) 
β-Actin FP TGT GGT GGT GAA GCT GTA GC 380 
β-Actin RP GAC GAC ATG GAG AAG ATC TGG 
B29 FP AGC CGG AGC TCC ATG GTG AAG 216 
B29 RP TGG CGC TGT CAC ATT TCT GC 
CD19 FP CGG GAC CCA GAA CCA GTA CG 247 
CD19 RP CTG CCC AAG GTT GGA GTC GT 
E2A FP GAC TCC GGG AGC GAG ATG AA 196 
E2A RP ATG AGG AAC CTG CGC TCC TG 
EBF1 FP CAT GTC CTG GCA GTC TCT GA 240 
EBF1 RP CAA CTC ACT CCA GAC CAG CA 
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FOXO1 FP GGA GAC AGC CCT GGG TAT CA 183 
FOXO1 RP GGA ATG CAC GTC CCC ATC TC 
Mb1 FP TCA GAG CCC TGC CTC TCC TC 199 
Mb1 RP ACT GGG GGC CCA TGT GAT GTT 
Pax5 FP TGG ACC GCG TGT TTG AGA GA 226 
Pax5 RP AGG GTT GTG CTC GCC AAG TC  
Rag1 FP CCT TTG AAA AGG CAC CCG AGG 207 
Rag1 RP GCC TGG CTT GGT GAA CTG CT 
VpreB FP GCT CAT GCT GCT GGC CTA TC 224 
VpreB RP TCC AAG GGA AGA AGA TGC TAA  
λ5 FP TGG AGC TTC AGT GGG AAG CA 152 
λ5 RP GGG TCC CAC CAC CAA AGA CA 
 
3.1.7.2 Oligonucleotides for mouse genotyping 
Oligonucleotide Sequence 5’→ 3’ Amplification Product 
(bp) 
Ebf1 FP GGA AAA GTT GCC TTC AAG TTG  
Ebf1 RP TGT AGA GGA GCT GGA GCC G 150 
Ebf1 Neo RP GCG ATG CCT GCT TGC CGA A 400 
 
3.1.7.3 Oligonucleotides for site-directed mutagenesis 
Oligonucleotide Sequence 5’→ 3’ 
Ebf1-S13A FP CAA CGG AGT GGA GCC AGT ATG AAG GAA GAG 
Ebf1-S13A RP CTC TTC CTT CAT ACT GGC TCC ACT CCG TTG 
Ebf1-S14A FP CAA CGG AGT GGA GGC GCT ATG AAG GAA GAG 
Ebf1-S14A RP CTC TTC CTT CAT AGC GCT TCC ACT CCG TTG 
Ebf1-S13A, S14A FP CAA CGG AGT GGA GCC GCT ATG AAG GAA GAG 
Ebf1-S13A, S14A RP CTC TTC CTT CAT AGC GGC TCC ACT CCG TTG 
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3.1.7.4 Oligonucleotides for D-J rearrangement of immunoglobulin 
heavy chain locus  
Oligonucleotide Sequence 5’→ 3’ 
DH3-1 FP AGG CTC TGA GAT CCC TAG ACA G 
GL5-1 RP CCC GGA CAG AGC AGG CAG GTG G 
DH5-1 RP ACA AGC TTC AAA GCA CAA TGC CTG GCT 
DH5-2 FP ACG TCG ACT TTT GTC AAG GGA TCT ACT ACT GT 
JH4 RP GGG TCT AGA CTC TCA GCC GGC TCC CTC AGG G 
GL3-2 FP CGA AGT ACC AGT AGC AC 
GL5-2 RP GAG TTG ACT GAG AGG ACA 
 
3.1.7.5 Oligonucleotides for cloning 
Oligonucleotide Sequence 5’→ 3’ 
αEbf1 FP GAA TTC ATG AAG GAA GAG CCG CTG GG 
αEbf1 RP CTC GAG TCA CAT GGG AGG GAC AAT CA 
Ebf1-ΔTAD FP GAA TTC ATG TTT GGG ATC CAG GAA AG 
Ebf1-ΔTAD RP CTC GAG CGA AGT GTT AGC AAG GGC TG 
αEbf1-ΔTAD FP GAA TTC ATG AAG GAA GAG CCG CTG GG 
αEbf1-ΔTAD RP CTC GAG CGA AGT GTT AGC AAG GGC TG 
 
3.1.7.6 Oligonucleotides for EMSA 
Oligonucleotide Sequence 5’→ 3’ 
Mb-1 FP CCC CGA CCC CAC GCA CTA GAG AGA GAC TCA 
AGG GAA TTG TGG 
Mb-1 RP CCC TGC ACC TGG GCT GGC CAC AAT TCC CTT GAG 
TCT CTC TC 
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3.1.7.7 Oligonucleotides for sequencing 
Oligonucleotide Sequence 5’→ 3’ 
MSCV-EcoR1-Ebf1 FP CTG CAG CAT CGT TCT GTG TT 
MSCV-Xho1-Ebf1 RP TAC GCT TGA GGA GAG CCA TT 
pCMVcyto-Ebf1 FP TAC ATC AAT GGG CGT GGA TA 
pCMVcyto-Ebf1 RP CCT ACT CAG ACA ATG CGA TGC 
pcDNA3.1-flag-Ebf1 FP TCG GAA GGT ACG CCC TCT TA 
pcDNA3.1-flag-Ebf1 RP TCC CAT ACA GGG CTT CAA CC 
 
3.1.8 Plasmids 
MSCV-IRES-GFP (MIG, Dr. Richard Moriggl, Ludwig Boltzmann Institute, Wien) 
The murine stem cell virus (MSCV) vector carries the Ebf1 gene (Dr. Silvia 
Hiechinger and Dr. Saihong Jin HMGU Munich) in front of an internal ribosomal entry 
site and the green fluorescent protein gene (IRES-GFP). The vector MIG-Ebf1 was 
used for Ebf1 site-directed mutagenesis (MIG-S13A), and αEbf1, Ebf1-ΔTAD and 
αEbf1-ΔTAD cloning. All of the modified MIG-Ebf1 were finally used with the 
retroviral packaging cell line GP+E86 cells.  
 
Helper-Plasmid (Dr. Richard Moriggl, Ludwig Boltzmann Institute, Wien) 
This vector is necessary for the beginning of replication and transfer of other 
plasmids from a donor to a recipient. Helper-plasmid was used for transfer of MIG-
mutant Ebf1, -αEbf1 and -deleted Ebf1 into retrovirus packaged GP+E86 cells. 
 
pBL-Lambda5-Luc (pBL-Luc empty vector: Dr. Ursula Zimbro Strobl, HMGU Munich)  
This vector contains the lambda5 promoter including 3 Ebf1 binding sites and the 
luciferase gene (Dr. Silvia Hiechinger, HMGU Munich). This vector was used in 
luciferase reporter assay.  
 
pcDNA3.1-Flag-Ebf1 (pcDNA3.1-Flag empty plasmid: Dr. Hermann Silje, MPI 
Munich) 
pcDNA3.1-flag- Ebf1-S13A, -S14A and -S13, 14A using for electrophoretic mobility shift 
assay were generated from pcDNA3.1-Flag-Ebf1( Dr. Saihong Jin, HMGU Munich). 
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pCMVcyto (Invitrogen Life Technologies) 
pCMV-Ebf1-S13A, Ebf1-S14A, Ebf1-S13,14A, αEbf1, Ebf1-ΔTAD and αEbf1-ΔTAD were 
generated from pCMVcyto-Ebf1 (Dr. Silvia Hiechinger) and used for the 
overexpression in luciferase reporter assay. 
 
pCMVcyto-LacZ (Dr. Ursula Zimber Strobl, HMGU Munich) 
This vector was used for over expression of the LacZ gene and normalization in 
luciferase reporter assay.  
 
3.1.9 Bacteria 
XL1-Blue 
This is a E.coli stain. The genotype is F’: Tu 10 proA + B laclq D (lacZ) M15/recA1 
end A1 gyr A96 (Nalr) thi hsd R17 (rk-mk +) glu V44 rel A1 lac. The original strain 
was purchased from Stratagene. 
 
3.1.10 Cell lines 
18-81 TK+ (Siden et al., 1979) 
Pre-B-cell line isolated from murine bone marrow provided by Dr. Hans-Martin-Jäck, 
Nikolaus-Fiebiger-Zentrum, Erlangen. The cell line was used for anti-Ebf1-S13 (p), and 
anti-Ebf1-S13 (p) S14 (p) phosphorylation antibodies test.  
 
Ba/F3 (Palacios et al., 1984 & 1985) 
IL-3-dependent pro-B cell line derived from murine bone marrow provided by Dr. 
Rudolph Grosschedl, MPI Freiburg. This cell line was used for electrophoretic 
mobility shift assay and luciferase reporter assay.  
 
HEK293T (Graham et al., 1977)  
Transformed fibroblast-like cell line derived from human embryonic kidney cells 
constitutively expressing the SV40 large T antigen. This cell line was used for the 
propagation of retroviruses with the murine stem cell virus and the protein expression 
test of mutant and truncated Ebf1. Dr. Rudolph Grosschedl, MPI Freiburg, provided 
this cell line.  
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GP+E86 (Markowitz et al., 1988) 
Fibroblast-like retrovirus packaging cell line that was isolated from murine embryo. 
This cell line contains the gag, pol and env genes of the Moloney murine leukemia 
virus. This cell line was used for generation of helper-free recombinant retrovirus to 
transduce murine cells. Dr. Stefan Bohlander, University of Munich Großhadern, 
provided this cell line. 
 
3.1.11 Mouse strain  
Ebf1-/- (Lin & Grosschedl, 1995) 
C57BL/6 transgenic mouse strain carries a targeted mutation in deletion of the Ebf1 
gene residing on chromosome 11. In genomic sequence, functionally important 
portion of the DNA-binding domain of Ebf1 was replaced with a neomycin-resistance 
gene cassette. This mouse strain carries the CD45.2 allele of the tyrosine 
phosphatase CD45.  
 
C57BL/6 (Charles River, WIGA) 
This mouse strain was used for generating the Ebf1-heterozygous mice to obtain a 
wild-type allele. In addition, he served the production of virgin wt bone marrow and 
spleen cells. This mouse strain carries the CD45.2 that is allogeneic the tyrosine 
phosphatase CD45. 
 
B6.2JL-Ptprca Pepcb /BoyJ (CD45.1; Charles River, WIGA) 
C57BL/6 mouse strain carries the CD45.1 allele of the tyrosine phosphatase CD45 
instead of CD45.2. These mice bone marrow cell was used as for Whitlock-Witte 
culture. 
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3.1.12 Software 
 
Software Function 
4Peaks 1.7.2 Analysis of DNA-Sequence 
Adobe Illustrator CS5 Vector Drawing Program 
BD FACSDiva Software Analysis of Flow Cytometry and Cell Sorting 
Cell Quest Becton Dickinson Acquisition and Analysis of Flow Cytometry 
FlowJo 9.3, Tree Star Inc. Analysis of Flow Cytometry and Cell Sorting 
Insilico Biotechnology Ligation Calculation  
LightCycler® SYBR Green Software Recording and Evaluation of Quantitativ Real-
Time PCR Reactions 
MecVector with Assembler 12.7.5 Analysis of Plasmid Sequence 
Primer3 Primer Design 
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3.2 Methods  
3.2.1 Molecular biology methods 
3.2.1.1 RNA 
3.2.1.1.1 RNA isolation from mammalian cells 
The total RNA was isolated following peqGOLD TriFastTM manufacturer’s protocol. 
FACSAriaTMIII sorted mammalian cells were collected and centrifuge at 160 g, 4 °C 
for 6 min. After removal of the supernatant, cells were lysed in 1 ml peqGOLD 
TriFastTM and incubated at room temperature for 5 min. Then, 0.2 ml chloroform 
(Sigma) was added. The whole samples were mixed vigorously and incubated at 
room temperature for 3 min. The organic and aqueous phases were separated by 
centrifugation (12000 g, 5 min at 4 °C). The upper aqueous phases was transferred 
into a new 1.5 ml tube and mixed with 0.5 ml chilled isopropanol and 1 µl of glycogen 
(Ambion). After 30 minutes incubation on ice, the total RNA was precipitated by 
centrifugation (12000 g, 15 min at 4 °C). The supernatant was discarded and the 
RNA pellet was washed with 1 ml 70% (v/v) chilled ethanol (DEPC water). After 
centrifugation (12000 g, 15 min at 4 °C) the supernatant was removed and the RNA 
pellet was dried at room temperature. Finally, the RNA pellet was resuspended in 20 
µl RNase free ddH2O. The concentration of isolated RNA was measured by 
photometric determination. The RNA were either directly used for cDNA synthesis or 
stored at -20 °C. 
 
3.2.1.1.2 cDNA synthesis 
cDNA was synthesized according to the manufacturer’s protocol of First-Strand 
cDNA Synthesis, using SuperscriptTM II (Invitrogen). 1ng – 5 µg of total RNA were 
gently mixed with 0.5 µg oligo (dT), 12-18 Primer (Invitrogen), 0.5 mM dNTP 
(Fermentas) and added dH2O up to 12 µl. The mixture was heated at 65 °C for 5 
minutes and quick chilled on ice. After a brief centrifugation to collect all contents of 
the tube, the 12 µl mixture was gently mixed with 1 x First-Strand Buffer, 5 mM DTT, 
40 U RNaseOUTTM and 200 U SuperScriptTM II (Invitrogen). The whole sample final 
amount was incubated at 42 °C for 50 min and inactivated at 70 °C for 15 min. The 
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final volume of the mixture is 20 µl. The cDNA was either directly used for rtPCR or 
stored at -20 °C.  
3.2.1.1.3 Quantitative real time polymerase chain reaction  
Gene expression analyses were performed according to the manufacturer’s protocol 
of LightCycle® 480 SYBR Green I Master (Roche). 1 µl of cDNA was gently mixed 
with 5 µl of SYBR Green Master (Roche), 1 µl FP (10 pmol), 1 µl RP (10 pmol) and 2 
µl ddH2O in 96-well microtiter plate. The oligonucleotides (see 3.1.7.1) were 
designed to be intron spanning using tools provided on the internet (Primer3). The 
96-well-microtiter plate was subsequently covered by LightCycle® 480 Sealing Foil 
(Roche) centrifuged for 2 min at 12000 g and run in LightCycle® 480 II machine 
(Roche). 
 
Real time PCR for Ebf1 target gene expressions were under this condition:  
Cycle step    Temperature  Time  Cycle 
Initial polymerase activation       95°C  10 min    1 
Denaturation          95°C  10 sec       45 
Annealing           65°C  10 sec    
Elongation          72°C  15 sec    
Creating the melting curve  65-97 °C    0.11 °C/sec     1 
 
Actin was used as a housekeeping gene.  All of the target genes cross point (CP) 
values were normalized to actin CP value. To verify the specificity of the amplified 
products, melting curve analysis were performed. 
 
3.2.1.2 DNA 
3.2.1.2.1 Genomic DNA isolation from mouse tail cells  
To isolate genomic DNA from mouse tail cells for genotyping, approximately 0.3 cm 
mouse tail tip was cut and incubated on Thermomixer compact (Eppendof) with 100 
µl lysis buffer (1x FirePol Polymerase Buffer (Solis BioDyne), 1.5 mM MgCl2, 40 µg/µl 
proteinase K (Ricaud Rothiot et al.)) at 55 °C, 400 rpm for at least 1 hour. After 
inactivating the proteinase K at 95 °C for 15 minutes, 1 µl of the solution from the 
genomic DNA was used in PCR reaction (3.2.1.2.3.1) 
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3.2.1.2.2 Genomic DNA isolation from mouse fetal liver cells 
To isolate genomic DNA of fetal liver cells from Ebf1-dificient mouse embryos 
(CD45.2), the cells were sorted (3.2.5.3) directly into lysis buffer (1x FirePol 
Polymerase Buffer (Solis BioDyne), 1.5 mM MgCl2, 40 µg/µl proteinase K (Ricaud 
Rothiot et al.)) and incubated on Thermomixer compact (Eppendof) at 55 °C, 400 
rpm for 1 hour. To inactivating the proteinase K, the mixture was heat at 95 °C for 15 
minutes. 5 µl of the solution was used in the PCR of D-J Rearrangement of 
Immunoglobulin Heavy Chain Locus reaction. 
 
3.2.1.2.3 Polymerase chain reaction (PCR) 
3.2.1.2.3.1 PCR for genotyping 
DNA fragments were amplified in PCR reactions for Ebf1 mouse genotyping. 
Genomic DNA isolated from mouse tail cells were gently mixed with 1 U FirePol DNA 
polymerase (Solis BioDyne), 1 x FirePol buffer B (Solis BioDyne), 0.5 mM MgCl2, 1 
mM dNTP (Fermentas), 1 pmol Ebf1 FP, 1 pmol Ebf1 RP, 1 pmol Ebf1 Neo RP 
(3.1.7.2.) and 17.9 µl ddH2O. Briefly spin down total 25 µl reagents, whole sample 
was run by PCR machine (DNA-Engine®; Bio-Rad). 
 
The PCR program for Ebf1 mouse genotyping is:  
Cycle step    Temperature  Time  Cycle 
Initial denaturation   95 °C    3 min  1  
Denaturation    95 °C           0.5 min  30 
Annealing    56 °C           0.5 min 
Extension    72 °C           0.5 min 
Final extension    72 °C     5 min  1 
       4 °C      hold 
The amplified PCR DNA was detected by 1.5% agarose gel.  
 
3.2.1.2.3.2 PCR for site-directed mutagenesis 
Ebf1 S13, and S14 were mutated following the manufacturer’s protocol of Quik 
Change® Site-Directed Mutagenesis Kits (Stratagene). 55ng MSCV-IRES-GFP-Ebf1 
(MIG-Ebf1; Dr. Silvia Hiechinger and Dr. Saihong Jin; 3.1.8), pCMVcyto-Ebf1 (Dr. 
Silvia Hiechinger; 3.1.8) or pcDNA3.1-Ebf1-Flag (Dr. Saihong Jin; 3.1.8) were 
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separately mixed with 1x buffer, 2.5 U Pfu Polymerase (Stratagene), 10 pmol FP, 10 
pmol RP (See 3.1.7.3), 1 mM dNTP (Fermentas) and 39 µl ddH2O. After spinning 
down the total 50 µl reagents, whole sample was run by PCR machine (DNA-
Engine®; Bio-Rad). 
 
The PCR program of Ebf1 S13 and S14 site-directly mutagenesis is:  
Cycle step    Temperature  Time  Cycle 
Initial denaturation   95 °C   0.5 min 1  
Denaturation    95 °C   0.5 min  16 
Annealing    55 °C      1 min 
Extension    68 °C      8 min 
       4 °C        hold 
 
 
The mutant Ebf1 was digested and transformed into XL1 Blue bacterial following the 
mutagenesis manufacturer’s protocol. After plasmid isolation (see 3.2.1.2.4.3), the 
sequence of mutant Ebf1 was control by sequencing. 
 
3.2.1.2.3.3 PCR for D-J rearrangement of immunoglobulin heavy 
chain locus 
DNA fragments of sorted cells were amplified in nested PCR reactions for D-J IgH 
locus rearrangement. 5 µl genomic DNA isolated from sorted cells was gently mixed 
with1 U FirePol DNA polymerase (Solis BioDyne), 1 x FirePol buffer B (Solis 
BioDyne), 0.5 mM MgCl2, 0.2 mM dNTP (Fermentas), 0.4 µM DH3-1 FP, 0.4 µM DH5-
1 RP, 0.4 µM GL5-1 RP (3.1.7.4.) and 30 µl ddH2O. After spinning down the total 50 
µl reagents, whole sample was run by PCR machine (DNA-Engine®; Bio-Rad) for 
the first round amplification.  
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The PCR for D-J IgH rearrangement locus was performed under this condition:  
Cycle step    Temperature  Time  Cycle 
Initial denaturation   95 °C    1 min  1  
Denaturation    95 °C    1 min  30 
Annealing    63 °C    1 min 
Extension    72 °C           1.5 min 
Final extension    72 °C             10 min   1 
       4 °C      hold 
 
 
2 µl of the first round amplified DNA was mixed with 1 U FirePol DNA polymerase 
(Solis BioDyne), 1 x FirePol buffer B (Solis BioDyne), 0.5 mM MgCl2, 0.2 mM dNTP 
(Fermentas), 2 µM DH5-2 FP, 2 µM JH4 RP, 2 µM GL3-2 FP, 2 µM GL5-2 RP  
(3.1.7.4.) and 34 µl ddH2O. After spinning down the total 50 µl reagents, whole 
sample was run again by PCR machine (DNA-Engine®; Bio-Rad) in the same 
program. 
 
The final PCR amplified DNA was loaded on 1.5% agarose gel for D-J IgH 
rearrangement locus determination.  
 
3.2.1.2.3.4 PCR for cloning   
For αEbf1, Ebf1-ΔTAD and αEbf1- ΔTAD cloning MIG-Ebf1 was amplified following 
the protocol of Thermo Scientific Phusion High-Fidelity DNA Polymerase. 500 ng 
MIG-Ebf1 plasmid (Dr. Silvia Hiechinger and Dr. Saihong Jin; 3.1.7) was gently 
mixed with 1 x Phusion HF buffer, 200 µM dNTPs, 0.5 µM primers, 0.02 U/µl Phusion 
DNA polymerase (Thermo Scientific) and dH2O up to 50 µl. αEbf1, Ebf1-ΔTAD and 
αEbf1- ΔTAD were amplified using primer pairs (3.1.7.5), which contain EcoRI 
recognition site at the 5’ end of the forward primer and Xhol recognition site at the 5’ 
end of the reverse primer. The total PCR mixture is run by PCR-machine (DNA-
Engine®; Bio-Rad). 
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PCR for Ebf1 deletions were performed under this condition:  
Cycle step    Temperature  Time  Cycle 
Initial denaturation   98 °C   30 sec  1  
Denaturation    98 °C   10 sec  25-35 
Annealing    69 °C   20 sec 
Extension    72 °C   15 sec/kb 
Final extension    72 °C      5 min   1 
       4 °C        hold 
The amplified DNA was loaded on 1.5% agarose gel to control the correct size of 
αEbf1, Ebf1-ΔTAD and αEbf1- ΔTAD. 
 
3.2.1.2.4 Gel-DNA extraction 
To purify PCR amplified DNA, αEbf1, Ebf1-ΔTAD and αEbf1- ΔTAD DNA was loaded 
on agarose gel. The size of wild type αEbf1 is 1746 bp, Ebf1-ΔTAD is 1284 bp and 
αEbf1-ΔTAD is 1239 bp. The band containing correct size of amplified DNA was cut 
out and dissolved in the same amount of Membrane Binding Solution (Promega). 
The DNA was purified by PCR Clean-Up System kit (Promega) following the 
manufacturer's protocol and eluted in 50 µl nuclease-free water, store at 4 °C or -
20 °C. 
 
3.2.1.2.5 DNA cloning  
3.2.1.2.5.1 Ligation  
To insert αEbf1, Ebf1-ΔTAD or αEbf1-ΔTAD into MIG, pCMVcyto and pcDNA3.1-
Flag vector ligation was performed. 50 ng of pJET1.2 vector was ligated with 150 ng 
of Wild type αEbf1, Ebf1-ΔTAD or αEbf1-ΔTAD. Following online ligation calculator 
(Insilico Biotechnology), the ratio of vector and insert DNA is 1 to 3, 5000 ng of MIG 
was ligated with 4127 ng αEbf1, 3035 ng Ebf1-ΔTAD or 2929 ng αEbf1-ΔTAD. 5000 
ng of pCMVcyto was ligated with 5363 ng αEbf1, 3944 ng Ebf1-ΔTAD or 3806 ng 
αEbf1-ΔTAD. 
 
The mixture of vector and insert DNA was gently mixed with 1 x reaction buffer and 5 
U of T4 DNA ligase (Thermo Scientific) filling in ddH2O up to 20 µl. The total mixture 
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was incubated at room temperature 5 min for pJET1.2 ligation and overnight for MIG 
and pCMVcyto ligation. 
 
3.2.1.2.5.2 Bacterial transformation  
To amplify the plasmid, 10 µl plasmid was mixed with 100 µl XL1 blue bacteria (3.1.9) 
and heated at 42 °C for 45 sec. The sample was cooled down on ice for 5 min. 200 
µl LB media, without ampicillin, was added into XL1 blue bacteria and incubated at 
37°C, 400 rpm for 30 min on Thermomixer compact (Eppendorf). The 310 µl mixture 
of XL1blue bacteria, LB media and plasmid was spread on ampicillin LB plate and 
incubated at 37 °C overnight.  
 
3.2.1.2.5.3 Bacterial culture and DNA isolation 
After overnight incubation, the colonies of transformed XL1 blue bacteria were 
carefully scraped from ampicillin LB plate and incubated in 100-200 ml ampicillin LB 
media at 37 °C overnight. 
 
Next day, the bacterial DNA was isolated using QIAGEN Plasmid Mini/Maxi Kit 
(QIAGEN GmbH) according to the manufacturer's instructions. 
 
3.2.1.2.5.4 DNA test digestion  
To test the correct insertion of αEbf1, Ebf1-ΔTAD or αEbf1-ΔTAD, 1 µl plasmid was 
gently mixed with 10 U of restriction enzyme and 1 x buffer (Thermo Scientific) filling 
in dH2O up to 20 µl. The mixture was incubated at 37 °C 1 hour, and then loaded on 
1.5% agarose gel.  
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All of the plasmids were digested as following:  
Cloning    Restriction enzyme  Buffer   Correct size (bp) 
pJET1.2- αEbf1  Xhol, EcoRI  0   1746  
pJET1.2-Ebf1-ΔTAD Xhol, EcoRI  0    1284 
pJET1.2-αEbf1-ΔTAD Xhol, EcoRI  0    1239 
MIG-αEbf1   BamHI, Spel  BamHI  1207 and 7102 
MIG-Ebf1-ΔTAD  BglII, Spel  B   1898 and 5691 
MIG-αEbf1-ΔTAD  BglII, Spel  B   1856 and 5691  
 
pCMVcyto-   Stul, BglIl  B   1748 and 4859 
αEbf1 
pCMVcyto-    Stul, BglII  B   1256 and 4937 
Ebf1-ΔTAD 
pCMVcyto-   Stul, BglII  B   1256 and 4895 
αEbf1-ΔTAD 
 
3.2.1.2.5.5 DNA sequencing 
50-100 ng/µl DNA and 100 pmol/µl sequencing primers (3.1.7.7) were send to 
Eurofins MWG Operon for sequencing. Sequencing data were read in MacVector 
software.  
3.2.2 Biochemical methods 
3.2.2.1 Protein preparation 
3.2.2.1.1 Protein isolation for western blot 
For the extraction of protein from cell line cells and murine cells, 1 x 107 cells were 
harvested and washed by PBS. Cell pellet was resuspended in 200 µl of lysis buffer 
(1% NonidetTM P40 (Sigma), 50 mM Tris/HCl, pH 8, 150 mM NaCl) and incubated on 
ice for 40 min. To minimize degradation or dephosphorylating of proteins, the lysis 
buffer protease inhibitors (Complete Mini EDTA-Free Tablets, Roche) and 
phosphatase inhibitors (Phosphatase Inhibitor Cocktail Tablets, Roche) were added 
according to the manufacturer’s instructions. Finally, the lysates were centrifuged for 
5 min at 18600 g, 4 °C. The supernatants were used for further analysis or stored at 
– 20 °C. 
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3.2.2.1.2 Protein isolation from Ba/F3 cells for electrophoretic 
mobility shift assay (EMSA) 
2 x 107 Ba/F3 cells were harvested and washed by pre-cold PBS for the extraction of 
protein from cells nuclear using in EMSA (3.2.2.2). The cell pellet was dissolved in 
200 µl sedimentation buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 
EGTA) freshly adding 1 mM DTT (Invitrogen Life Technologies) and 1 mM proteinase 
inhibitor and incubated for 15 min on ice. Afterwards, 12.5 µl of 10% NonidetTM P 40 
(Sigma) were added to specifically break cell membrane, without impairing the 
nuclear membrane. The mixture was strongly shaken for 5 min and subsequently 
centrifuged for 10 min at 18600 g, 4 °C. The pellet was washed in 1.5 ml 
sedimentation buffer and centrifuged again. The cell pellet was resuspended in 40 µl 
of protein extraction buffer (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1mM 
EGTA) freshly adding 1 mM DTT (Invitrogen Life Technologies) and 1 mM proteinase 
inhibitor (Complete Mini EDTA-Free Tablets, Roche) and then incubated for 30 min 
at 4 °C with strong shake. After 10 min centrifugation (18600 g, 4 °C), supernatant 
was used for further analysis or shock frozen in liquid nitrogen and sored at - 80 °C. 
 
3.2.2.1.3 Protein isolation from Ba/F3 cells for luciferase-reporter-
assay 
1 x 107 Ba/F3 cells were harvested and washed with pre-cooled PBS for the 
extraction of protein used in luciferase reporter assays (3.2.2.3). The cell pellet was 
resuspended in 100 µl luciferase protein extraction buffer (25 mM Tris/HCl, pH 7.8, 
and 10% glycerol, 1% Triton X-100, 2 mM EDTA, 2 mM DTT (Invitrogen Life 
Technologies)) and incubated on ice for 15 min. The mixture was centrifuged (18600 
g) for 15 min at 4 °C. The supernatant was frozen in liquid nitrogen and stored at -
80 °C. 
 
3.2.2.1.4 Phosphatase-treatment of protein extract 
For phosphatase treatment of protein extracts from 18-81 TK+ cells (3.1.10), 20 µg of 
total protein were incubated with 15 U calf intestinal alkaline phosphatase (CIP, New 
England Biolabs, 10 U/µl) and 1 x NEBuffer3 (New England Biolabs) in a total 
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volume of 40 µl. The mixture was incubated for 1 h at 37 °C and used for western 
blot (3.2.2.1.6). 
 
3.2.2.1.5 Protein concentration measurement 
For the determination of extracted protein concentration, the BCA Protein Assay 
Reagent (Thermo Scientific) was used, following the manufacturer’s instructions. 
Reagent A was mixed with reagent B in the ratio 50:1. To create a calibration curve  
BSA (PAA Laboratories) was added at the concentration of 0, 2, 4, 8, 10, 15 µg/µl 
separately into 400 µl total volume of reagent A/reagent B mixture. To determine the 
concentration of extracted protein, 1 µl of protein solution was added into 399 µl of 
reagent A/reagent B mixture. After 30 min incubation at 37°C, the absorbance at a 
wavelength of 562 nm was determined by photometry (BioPhotometer; Eppendorf).  
 
3.2.2.1.6 SDS-polyacrylamide gel electrophoresis 
For protein separation, 20 µg protein was mixed with Laemmli buffer (20 % glycerol, 
250 mM Tris, pH 6.8, 5 % 2-mercaptoethanol (Sigma), 4 % SDS, 0.01 % 
bromophenolblue) and shaken at 95 °C for 15 min. Subsequently, the proteins were 
separated by using a SDS-PAGE comprising a 5 % stacking gel (250 mM Tris/HCl 
pH 6.8, 0.1% SDS, 5% Rotiphorese® Gel 40 (Roth; Acrylamid/Bisacrylamid 29:1); 
0.1% APS, 0.004% TEMED (Ricaud Rothiot et al.) and a 10-12% resolving gel (375 
mM tris/HCl pH 8.8, 0.1% SDS, 10-12% Rotiphorese® Gel 40; 0.1% APS, 0.004% 
TEMED). PageRulerTM prestained protein ladder (Fermentas) was used as a protein 
size marker. The gel was run in a Mini Trans-Blot Cell® (Bio.Rad) electrophoresis 
chamber, using 1 x SDS running buffer (25 mM Tris, 1 % SDS, 192 mM glycine) at 
160 V.  
 
3.2.2.1.7 Transfer of electrophoretic separated protein to 
nitrocellulose membranes 
After SDS-PAGE, the separated proteins were transferred to a nitrocellulose 
membrane (Protran) using Semi-Dry Transfer Cell apparatus (BioRad). The 
nitrocellulose membrane and gel blotting paper (Whatman GmbH, 1.2 mm) were 
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placed in 1x transfer buffer (20 % ethanol, 80 % 1 x SDS running buffer (25 mM Tris, 
1 % SDS, 192 mM glycine)) before the transfer. The nitrocellulose membrane was 
placed on the top of SDS-PAGE and stacked with gel blotting paper on both side as 
a sandwich. The transfer was performed at 10 V, 300 mA for 1.5 hours. To check the 
transfer efficiency, the nitrocellulose membrane was stained in Ponceau S solution 
(2 % Ponceau S red, 30 % trichloroacetic acid and 30 % sulfosalicylic acid) for few 
seconds. After washing away the Ponceau S solution, the membrane was ready for 
immuno-detection.  
 
3.2.2.1.8 Immuno-detection of protein  
The proteins transferred onto the nitrocellulose membrane were analysed by 
immuno-detection. The membrane was incubated with 5 % milk (5 % dry milk power 
in 0.4 % Tween® 20) or 5 % BSA (5 % dry BSA powder in 0.4 % Tween® 20) for 30 
minutes at room temperature. The primary antibodies were incubated with 
membranes in 5 % milk or 5 % BSA solution in pre-tested dilution (3.1.6.2) at 4 °C 
with gentle shaking. Subsequently, the membrane was washed three times for 10 
minutes each in 1x TBS + 0.4 % Tween® 20. According to the primary antibody, the 
secondary antibody was diluted appropriately (3.1.6.2) in the same solution as 
primary antibody at RT for 45 minutes with gentle shaking. After washing three times 
in 1x TBST for 10 min each, the membrane was incubated with ECL detection 
reagent (1 ml reagent A (0.1 M Tris/HCl pH 8.6, 0.25 mg/ml Luminol sodium salt 
(Sigma)), 100 µl reagent B (DMSO (Roth), 1.1 mg/ml p- Coumaric acid (Sigma)), 0.3 
µl reagent C (30% H2O2 )) for few minutes. The membrane was placed onto a light 
sensitive film (Medical X-Ray Film Blue Screen Sensitive (CEA GmbH) and 
developed in a X-ray film developing machine TYPON Optimax (Raymed Imaging). 
 
3.2.2.2 Electrophoretic mobility shift assay (EMSA) 
3.2.2.2.1 Preparation of oligonucleotides 
The complementary oligonucleotides (3.1.7.6) at the same concentration (250 ng/µl) 
were resuspended in annealing buffer (10mM Tris/HCl pH7.4, 10 mM MgCl2, 50 mM 
NaCl) and heat up to 95 °C for 10 minutes in a Thermomixer compact (Eppendorf). 
After switching the Thermomixer compact off, the samples were incubated in the 
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Thermomixer compact until the temperature cooled down to room temperature. For 
the image of DNA-binding, the double-stranded oligonucleotides were radioactively 
labelled or stored at -20 °C for future work. 
 
3.2.2.2.2 Labelling and purification of oligonucleotides 
To label double-stranded oligonucleotides the providing Klenow fragment of E. coli 
DNA Pol I was used as a 3’ to 5’ end labelling. For this purpose, 2 µl oligonucleotides 
(25 ng/µl), 2 µl Klenow fragment (Roche Diagnostics, 2 U/µl), 2 µl NEB2 buffer (New 
England Biolabs, 10 x), 5 µl 32P-alpha-dCTP (Hartmann Analytic, 3000 Ci/mol), 2 µl 
dNTPs (dATP, dGTP, dTTP, 500 µM; Fermentas) and 7 µl ddH2O were gently mixed 
and incubated at 37 °C for 1 hour.  Subsequently to purify the labelled 
oligonucleotides, TE buffer (10 mM Tris, pH 8, 1 mM EDTA) and illustra NICK 
Columns (GE Healthcare Life Sciences) were used following the manufacturer’s 
protocol. Afterward, scintillation counter (BioScan, Inc) were used following 
manufacturer’s protocol to count the amount of labelled oligonucleotides. Labelled 
oligonucleotides were stored until use at -20 °C. 
 
For preparing unlabelled oligonucleotides, 2 µl oligonucleotides (250 ng/µl), 2 µl 
Klenow fragment (2 U/µl), 2 µl NEB2 buffer (10 x), 2 µl of dNTPs (dATP, dCTP, 
dGTP, dTTP; 500 µM) and 12 µl ddH2O were incubated at 37 °C for 1 hour. The 
oligonucleotides were stored until use at -20 °C. 
 
3.2.2.2.3 Buffer preparation  
For the binding reaction of proteins and oligonucleotides, binding buffer was 
prepared. 5 µl 4 x binding buffer (40 mM HEPES pH 7.9, 280 mM KCl, 4 mM DTT 
(Invitrogen Life Technologies), 16 % Glycerin, 4 mM EDTA, 10 mM MgCl2), 2 µl poly 
dI-dC (1 mg/ml, (Sigma)) and 2 µl BSA (1 mg/ml, (PAA Laboratories)) were mixed 
with 3 - 4 µg protein from Ba/F3 cell lysates (3.2.2.1.2) and incubated on ice for 5 
minutes. Subsequently, 2 µl radioactively labelled or unlabelled oligonucleotides and 
in some cases 2 µl Anti-FLAG® M2 antibody (3.1.6.2) was added to the binding 
buffer mixture, adding ddH2O to a final volume 20 µl. This sample was incubated on 
ice for 30 minutes and then loaded on a non-denaturing polyacrylamide gel.  
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3.2.2.2.4 Gel running and detection 
For the non-denaturing polyacrylamide gel (4 % Rotiphorese® Gel 40 (Roth), 0.5 x 
TBE pH8.3, 0.1 % APS (Ricaud Rothiot et al.) and 0.003 % TEMED (Ricaud Rothiot 
et al.)) running, 1 x TBS (pH 8.3) buffer was used. The protein, oligonucleotides and 
antibodies were separated at 130 V for 2 hours at 4 °C. Subsequently, the 
polyacrylamide gel was dried on a gel blot paper (Whatman Ltd., 0.34 mm) for 1 hour 
using a gel dryer (Bio-Rad) with vacuum and temperature at 80 °C. Finally, the dried 
gel was incubated with a light-sensitive film (Kodak Biomax MS Film, (Sigma)) at - 
80 °C for 4 hours. The film was developed in the developing machine (Raymed 
Imaging TYPON Optimax). 
 
3.2.2.3 Luciferase-reporter-assay 
3.2.2.3.1 Luciferase-measurement 
To measure luciferase activity, 10 µl Ba/F3 cell protein extract (3.2.2.1.3) was added 
into a 96 well Microplate (LumitracTM 2000, (U.S. Scientific)). Additionally, 50µl 
luciferase assay buffer (20mM Tricin, 1 mM magnesium-carbonat pentahydrate, 3 
mM Mg2SO4, 0.1 mM EDTA, 33.3 mM DTT (Invitrogen Life Technologies), 270 µM 
acetyl-Coenzyme A (Roche Diagnostics), 470 µM luciferin (Roche Diagnostics), 530 
µM ATP disodium salt (Roche Diagnostics)) for each sample were prepared. The 
measurement of bioluminescence was performed using a luminometer (Berthold 
Detection Systems) at 560 nm wavelength and luciferase activity was calculated by 
normalizing to the β-galactosidase activity (3.2.2.3.2). 
 
3.2.2.3.2 β-Galactosidase measurement 
To normalise the transfection efficiency, a plasmid encoding gene lacZ was co-
transfected in reporter assay. To measure β-galactosidase activity, 10 µl Ba/F3 cell 
protein extraction (3.2.2.1.3) were mixed with 100 µl β-galactosidase assay buffer 
(100 mM Na-P, pH8.0; 1 % Galacton Plus® Chemiluminescent Substrate for β-
galactosidase (Applied Biosystems), 1 mM MgCl2) and incubated for 15 minutes at 
RT. Additionally, 50 µl β-galactosidase amplification buffer (0.2 M NaOH, 10% 
EmeraldTM Enhancer (Applied Biosystems)) was used for the luminometer (Berthold 
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Detection Systems). The β-galactosidase measurement was performed using a 
luminometer at 475 nm wavelength. 
 
3.2.3 Cell culture 
3.2.3.1 General cell culture techniques 
All cell culture procedures described below were carried out under a forced airflow 
hood (Thermo Scientfic) and performed using sterile solutions and disposable 
pipettes (Corning Incorporated). Cells were cultured in the respective cells adapted 
media (3.2.3.2) and incubated in a CO2 incubator (Binder) at 37 °C with 5% CO2 and 
95% humidity. Adherent cells and suspension cells were passaged every 3-4 days 
and washed in sterile PBS (Gibco BRL) using centrifugation at 160 x g for 6 minutes. 
 
3.2.3.2 Cell culture media 
18-81 TK+: 
RPMI 1640 (Gibco BRL)  
Heat- inactivated FCS (PAA Laboratories) 10% 
Sodium Pyruvate (100 mM; Gibco BRL) 1% 
Penicillin/Streptomycin (10.000 U/ml & 10.000 µg/ml, Gibco BRL) 1% 
β-Mercaptoethanol (Sigma) 500 µM 
 
Ba/F3: 
RPMI 1640 (Gibco BRL)  
Heat- inactivated FCS (PAA Laboratories) 10% 
Filtered IL-3-containing WEHI-3B supernatant 10% 
L-Glutamine, 200 mM (100 x; Gibco BRL) 1% 
Penicillin/Streptomycin (10.000 U/ml & 10.000 µg/ml, Gibco BRL) 1% 
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HEK293T and GP+E86: 
DMEM (Gibco BRL)  
Heat- inactivated FCS (PAA Laboratories) 10% 
L-Glutamine, 200 mM (100 x; Gibco BRL) 1% 
Penicillin/Streptomycin (10.000 U/ml & 10.000 µg/ml, Gibco BRL) 1% 
 
3.2.3.3 Cell counting 
The cell number was determined using CASY TTC (Innovatis) according to the 
manufacturer’s instructions. 
 
3.2.3.4 Thawing and freezing of cells 
Adherent cells and suspension cells were fed with fresh medium one day before 
freezing. 1 x 106 cells were washed with sterile PBS and centrifuged at 160 x g for 6 
minutes. The cells were resuspended in freezing medium (10% DMSO (Roth), 90% 
heat inactivated FCS (PAA Laboratories)) and stored in a Cryo TubeTM Vials (Nunc 
GmbH). In order to continuously and slowly cool down the cells,  the tubes were 
stored in a isopropanol freezing container (Nalgene, USA) at - 80 °C for 24 hours and 
then transfered into liquid nitrogen (- 196 °C) for long time storage. 
 
For thawing, the cells were rapidly warmed to 37 °C in a sterile water bath and gently 
added to 10 ml pre-warmed corresponding culture medium. To remove the DMSO, 
the cells were centrifuged and resuspended in fresh medium for further cultivation. 
 
3.2.3.5 Detachment of adherent cells 
Adherent cell lines (HEK293T and GP+E86) were detached by brief treatment with 
the proteolytic enzyme trypsin (trypsin-EDTA; 0.05%, Gibco BRL). For this purpose, 
the cells were gently washed with sterile PBS and then incubated with pre-warm 1 ml 
trypsin for 2-5 min at 37 °C. The enzyme reaction was stopped via adding 10 ml 
respective culture medium. After a centrifugation, the cells were either used for 
further cultivation or further analysis. 
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3.2.3.6 Transient transfection of mammalian cells 
3.2.3.6.1 Transient transfection of HEK293T cells by PEI 
For transient transfection, 7.5 x 105 HEK293T cells were cultured in a 10 cm cell 
culture dish 24 hours before transfection. Afterwards, the cells were incubated with 3 
ml DMEM (Gibco BRL) + 1% FCS (PAA Laboratories) for 20 minutes. Meanwhile, 6 
µg DNA were mixed with 200 µl OptiMEM® (Gibco BRL) and 12 µl 
Polyethylenenimin (PEI,1 mg/ ml; Gibco BRL) and incubated at RT for 20 minutes.  
The 200 µl DNA, OptiMEM® and PEI mixture were slowly added to 1% FCS DMEM 
cultured HEK293T cells and incubated for 4 hours in cell culture incubator. 
Subsequently, the transfection medium was replaced by normal corresponding 
culture medium (3.2.3.2) and cells were kept 24 to 48 hours in cell culture incubator. 
 
3.2.3.6.2 Transient transfection of Ba/F3 cells by electroporation  
Transient transfections of Ba/F3 cells were performed for EMSA (3.2.2.2) and 
luciferase reporter assay (3.2.2.3) to investigate the biochemical function of Ebf1. 
The cells were fed with their appropriate medium (3.2.3.2) 24 hours before 
transfection. 1 x 107 cells/transfection were washed three times with RPMI 1640. 
After the last centrifugation, the cell pellet was resuspended in a mixture of 300 µl 
OptiMEM® and 20 µg plasmid (see below) and transferred to an electroporation 
cuvette (Wuelfing and Brandau). Electroporation was performed using the Gene 
Pulser® II (BioRad) at 230 V and 975 µF. Transfected cells were immediately 
transferred into 20 ml pre-warmed culture medium in a 6-well-plate (Becton 
Dickinson, GmbH) and incubated for 24 to 48 hours in cell culture incubator.  
 
The plasmids using for EMSA transfection were: pcDNA3.1-mock-Flag, -Ebf1-Flag, -
Ebf1-S13A-Flag, -Ebf1-S14A-Flag and -Ebf1-S13, 14A-Flag. 
 
The plasmids using for luciferase reporter assay transfection were: pCMV-mock, -
Ebf1, -Ebf1-S13A, -Ebf1-S14A, -Ebf1-S13, 14A, -αEbf1, Ebf1-ΔTAD and -αEbf1-ΔTAD. 
Each plasmid was mixed with pBL-Lambda5-Luc or pBL-empty vector and 4 µg 
pCMVcyto-LacZ vector (3.1.8).  
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3.2.3.7 Preparation of GP+E86 packaging cells and retroviral 
transduction of murine cells 
3.2.3.7.1 Preparation of retrovirus packaging GP+E86 cells 
To produce retrovirus-packaging GP+E86 cells, HEK293T cells were first transfected 
by 6 µg MSCV-IRES-GFP (MIG)-mock, -Ebf1, -Ebf1-S13A, -Ebf1-S14A, -Ebf1-S13, 14A 
and 2 µg helper-plasmid (3.1.8) using PEI (3.2.3.6.1). 48 hours after transfection, the 
HEK293T cell culture supernatant containing viral particles was filtered through a 
sterile syringe filter (Millipore, 0.22 µm) and added onto GP+E86 cells growing in a 
10 cm cell culture dish. To increase the efficiency of infection, 6 µg/ml polybrene 
(Sigma) were added to the GP+E86 cells supernatant. This process was repeated 4-
6 times every 8-12 hours. In order to obtain maximum virus titers, infected GP+E86 
cells, which should express GFP protein, were sorted by flow cytometry (3.2.5.2) two 
times. Sorted cells now had a genomic integration of the retrovirus constructs. The 
percentage of the gag, pol and env genes of the Moloney murine leukemia virus are 
released into the cell culture supernatant permanently by GP+E86 cells, which was 
used to transduce murine cells in the future.  
 
3.2.3.7.2 Retroviral transduction of murine cells 
For retroviral transduction of murine cells (CD45.2 Ebf1-deficient fetal liver cells), 2 x 
106 cells were added to a 10cm cell culture dish retrovirus-producing GP+E86 culture 
medium (RPMI 1640, 10 % FCS, Penicillin/Streptomycin (10.000 U/ml & 10.000 
µg/ml). 10 ng/ml IL-3, 5 ng/ml IL-6 and 10 ng/ml SCF (R & D Systems) were used for 
co-culture. After 48 hours incubation of the co-culture in a cell culture incubator, 
transduced fetal liver cells were washed with sterile PBS and used for Whitlock-Witte 
culture (3.2.3.8).  
 
3.2.3.8 Whitlock-Witte culture of murine bone marrow cells and fetal 
liver cells 
CA Whitlock and ON Witte established culture condition that support the expansion 
of B cells from primary murine bone marrow cells in 1982 (Whitlock C.A., 1982). This 
culture system is used for in vitro differentiation of Ebf1-deficient and retrovirally 
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reconstituted hematopoietic cells. 13.5 x 106 CD 45.1 wild type murine bone marrow 
cells were isolated (3.2.4.2.2) and cultured with 13.5 ml RPMI 1640 medium, which 
was mixed with 5 % heat-inactivated FCS (PAN Fetal Bovin Swe. Org. South 
America) and 1.7 µl mercaptoethanol (Sigma) for 24 hours as a feeder cells. Then 
transduced CD45.2 fetal liver cells (3.2.3.7.2) were co-cultured with the feeder cells 
and incubated for ten to fourteen days. The co-culture cell medium was partially 
changed every three or four days until the cells were analysis by FACSAriaTMIII flow 
cytometer (BD Biosciences). 
 
3.2.4 Mouse analysis 
3.2.4.1 Generation of Ebf1-deficient embryos 
To isolate Ebf1-deficient fetal liver cells (3.2.4.2), two heterozygous Ebf1 mice 
(3.1.11) were crossed. The 14.5 to 16.5 days old Ebf1-deficient (E14.5 – E16.5) 
embryos were defined by genotyping of their tails (3.2.1.2.3.1). 
 
3.2.4.2 Isolation of organs and cells from mice 
3.2.4.2.1 Isolation of fetal liver cells from mouse embryos 
To isolate fetal liver cells, the whole fetal liver from Ebf1-deficient mouse embryos 
(E14.5 – E16.5) was isolated carefully. The tissue was forced through a 70-micron 
nylon mesh and added into culture medium (RPMI 1640, 10 % FCS, 
Penicillin/Streptomycin (10.000 U/ml & 10.000 µg/ml). Subsequently, the fetal liver 
cells were co-cultured with transduced retrovirus packaging GP+E86 cells (3.2.3.7.1) 
and used for Whitlock-Witte culture (3.2.3.8). 
 
3.2.4.2.2 Isolation of mouse bone marrow 
For the isolation of bone marrow, 3-24 week old femur and tibia were isolated.  
The bone marrow was flushed out with sterile PBS using a syringe (0.4 x 20 mm, G x 
3/4, Size 20, Brown) and then flushed through a 100-micron nylon mesh (BD GmbH). 
The bone marrow cells were used in Whitlock-Witte cultures (3.2.3.8) or Hardy B cell 
fraction sorting (3.2.5.1). 
 
  
  
69 
3.2.5 Flow cytometry 
3.2.5.1 Purification of hardy B cell fraction sorting 
 A method for the fractionation of B cells was established by Richard R. Hardy and 
Kyoko Hayakawa (1993). Murine B cell development was separated into fractions A, 
B and C in bone marrow and fractions D, E and F in the spleen using a combination 
of four different cell surface markers. For fractions A-C, cell surface marker B220+ 
and CD43+ bone marrow cells were further separated using Bp1 and CD24 (fraction 
A: BP1-, CD24-; fraction B: BP1-, CD24+; fraction C: BP1+, CD24+). 
 
To isolate fraction A-C, wild type mouse bone marrow cells were isolated (3.2.4.2.2). 
2 x 107 bone marrow cells were resuspended in 500 µl PBS and incubated with 1 µl 
anti-B220, -CD43, -BP1 and -CD24 antibodies for 25 minutes at 4 °C. The stained 
cells were washed once with PBS and resuspended in 1 ml PBS. The bone marrow 
cells were sorted using a FACSAriaTMIII flow cytometer (BD Biosciences) directly into 
PBS. Purified fraction A-C cells were collected by centrifugation and cell pellets were 
sorted at -20 °C or used for protein isolation (3.2.2.1.1) for western blot.  
 
3.2.5.2 GP+E86 cells sorting of GFP positive retroviruses 
To increase the virus titer of MIG infected GP+E86 cells (3.2.3.7.1), cells were sorted 
with a FACSAriaTMIII flow cytometer. The infected GP+E86 cells (GFP +) were 
detached (3.2.3.5) and washed by PBS, and then directly sorted into corresponding 
culture medium and cultured with ciprobay (5µl/ml of medium, Bayer). This sorting 
process was repeated two or three times and subsequently the GFP positive 
GP+E86 cells were used for retroviral transduction of murine cells (3.2.3.7.2) 
 
3.2.5.3 Cells sorting of transduced fetal liver cells  
To investigate the influence of Ebf1-S13, S14 phosphorylation, αEbf1 and truncated 
Ebf1 on target gene expression, GFP and CD45.2 positive transduced fetal liver cells 
were sorted. Ebf1-deficient CD45.2 fetal liver cells were transduced by MIG based 
plasmid (3.2.3.7), which contain different modified Ebf1 and GFP. The transduced 
fetal liver cells were co-cultured with Whitlock-Witte cells for ten to fourteen days 
(3.2.3.8) before sorting. The whole Whitlock-Witte co-culture cells were collected and 
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washed by PBS. The cell pellets were resuspended by 500 µl PBS and incubated 
with 1 µl anti-CD45.2, 1 µl anti-CD19-Biotin and 1 µl Streptavidin-PE (3.1.6.3) 
antibodies for 25 minutes at 4 °C. After washing the stained co-culture cells with 
PBS, the GFP and CD45.2 double positive cells were sorted directly into PBS and 
used for RNA isolation (3.2.1.1.1). 
 
3.2.6 Statistics 
The mean values, standard deviation and significance values (P) shown in the 
results were calculated by Microsoft Excel 2011. The P values were calculated from 
biological triplicate experiments. Real time PCR analyses were repeated as a 
technical triplicate and the dates were analysed using ΔCp method. 
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4 Results 
4.1 Generation of truncated Ebf1 and mutant Ebf1 
4.1.1 Generation of mutant Ebf1  
Ebf1 is a transcription factor (Hagman and Lukin 2005). Two promoters (α and β) 
generate two different protein isoforms and regulate their expression. αEbf1 is 15 
amino acids shorter than βEbf1 and the corresponding α promoter locates 4.4 kb 
upstream of the β promoter. The α promoter is indirectly regulated by IL7 and directly 
regulated by E2A and Ebf1, and the β promoter is associated with Pax5 and Pu.1 in 
B cells (Roessler et al. 2007b). 
 
In the pre-B cell line 18-81 TK+, Ebf1 is phosphorylated at S13 and S14 (Dr. Gerald 
Burgstaller and Dr. Hakan Sarioglu, HMGU Munich), which are only present in the 
longer isoform βEbf1 (Roessler et al. 2007b). To clarify the function of 
phosphorylated S13 and S14 in normal B cell development, we performed site-directed 
mutagenesis of Ebf1 in the retroviral vector MSCV-IRES-GFP-Ebf1 (MIG-Ebf1; Dr. 
Silvia Hiechinger and Dr. Saihong Jin; 3.1.8), resulting in the replacement of the 
serine residues with alanine. Serine has a hydroxyl group that can be phosphorylated 
by kinases, which is missing in the structurally similar alanine. We generated three 
constructs including mutations of S13 to alanine (S13A), S14 to alanine (S14A) and S13 
and S14 to alanine (S13, 14A; Figure 11A).  After the site-directed mutagenesis, the 
PCR amplified Ebf1-mutants were transformed into bacteria for plasmid isolation, 
and were controlled by sequencing. Expression of Ebf1-mutant proteins was 
investigated by western blot 24 hours after transfection of HEK293T cells (Figure 
11B). The protein expression is comparable to wild type Ebf1 in HEK293T cells. 
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Figure 11 Generation of mutant and truncated Ebf1 
 (A) Left panel: schematic diagram of the molecular structure of serine and alanine. 
Right panel: schematic overview of the mutations introduced into Ebf1. Serine 13 and 
14 of Ebf1 were mutated to alanine either alone or in combination.  
(B) Western blot analysis of mutant Ebf1 protein expression 24 hours after 
transfection of HEK293T cells. Actin was used as a loading control. Mock is empty 
MIG vector transfection. Each transfection was performed 3 times. 
(C) Plasmid maps show the short isoform of Ebf1 (α) and the truncated isoform 
lacking the transactivation domain (ΔTAD). αEbf1, Ebf1-ΔTAD, and αEbf1-ΔTAD 
were amplified using forward primer containing EcoRI at the 5’ end and reverse 
primer containing Xhol at the 5’ end. The amplified PCR products were ligated into 
MSCV-IRES-GFP (MIG) vector via the restriction site EcoRI and XhoI. 
(D) Schematic representation of the protein structure of αEbf1, Ebf1-ΔTAD and 
αEbf1-ΔTAD. The transactivation domain of Ebf1 starts at amino acid 429 and ends 
at amino acid 591; Ebf1-ΔTAD begins at amino acid 1 and ends at amino acid 429; 
αEbf1-ΔTAD begins at amino acid 15 and ends at amino acid 429 of wild type Ebf1. 
(E) Western blot analysis of αEbf1, Ebf1-ΔTAD and αEbf1-ΔTAD expression 24 
hours after transfection of HEK293T cells. Actin was used as a loading control. n = 3 
for each transfection and western blot. 
 
4.1.2 Generation of αEbf1 and truncated Ebf1  
To clarify the function of the first 15 amino acids, which are only present in βEbf1 and 
of the transactivation domain in B cell development, we generated wild type αEbf1, 
βEbf1 without the transactivation domain (βEbf1- ΔTAD) and αEbf1-ΔTAD from the 
MIG-βEbf1 plasmid. αEbf1 and truncated isoforms of Ebf1 were amplified using a 
forward primer containing EcoRI at the 5’ end and reverse primer containing Xhol at 
the 5’ end (Figure 11C). αEbf1 and truncated Ebf1 were inserted separately into the 
MIG vector (Figure 11C), which is a retroviral system allowing the introduction and 
expression of target genes in primary murine cells. The ligations of restriction sites 
were performed as described in 3.2.1.2.5.1. The correct insertion was controlled by 
restriction digest and sequencing. 
 
To confirm protein expression, the MIG-αEbf1 and MIG-truncated Ebf1 plasmids 
were transfected into HEK293T cells via polyethylenimine (PEI). 24 hours after 
transfection, HEK293T cells were harvested for protein isolation. Western blot was 
performed to detect the protein expression (Figure 11E). The translational start site 
of wild type αEbf1 is 45bp downstream of βEbf1 (Roessler et al. 2007b) 
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corresponding to 62.97kD of αEbf1 and 64.48kD of βEbf1 protein size. βEbf1-ΔTAD 
protein is 48.15kD and αEbf1-ΔTAD protein is 46.64kD (Figure 11D and 11E). αEbf1 
and truncated isoforms of Ebf1 show comparable expression to βEbf1 in transfected 
HEK293T cells.  
 
4.2 Serine 13, 14 and TAD of Ebf1 are required for B cell 
development 
In Ebf1-deficient mice, B cell differentiation is blocked at the pre-pro B cell stage (Lin 
and Grosschedl 1995). The ectopic expression of Ebf1 in hematopoietic progenitors 
from the fetal liver of Ebf1-deficient mice restores B cell development (Pongubala et 
al. 2008). CD19 is a surface antigen from the pro-B cell stage, whose expression is 
completely missing in absence of Ebf1 (Rolink et al. 1993). The role of Ebf1 in B cell 
development is well studied, however, post-translational modifications of Ebf1 and 
their function in B cell development are completely unclear. 
 
The biological function of the phosphorylation of S13 and S14 of βEbf1, αEbf1 and 
TAD in B cell differentiation was analysed by an established long-term cell culture 
system that supports the B cell differentiation in vitro (Whitlock-Witte culture) 
(Whitlock and Witte 1982). Fetal liver cells (CD45.2) from Ebf1-deficient mouse 
embryos (E14.5-E16.5) were isolated and co-cultured with retrovirus producing 
GP+E86 cells for Ebf1-S13A, -S14A, -S13, 14A, αEbf1, Ebf1-ΔTAD, or αEbf1-ΔTAD. 
Meanwhile, bone marrow cells were isolated from CD45.1 mice to generate a 
Whitlock-Witte culture (3.2.3.8). Following the two-day retroviral transduction, the 
fetal liver cells (CD45.2) were co-cultured with the feeder layer cells (CD45.1) for ten 
to fourteen days (Figure 12) to allow B cell development.  
 
After ten to fourteen days WW culture, the transduced fetal liver cells were analysed 
by flow cytometry for expression of CD19. The CD45.1 and CD45.2 system allowed 
distinction of Ebf1-deficient fetal liver cells (CD45.2) from wild type CD45.1 mice 
bone marrow cells. The infected cells co-express GFP via a downstream IRES-GFP 
cassette, distinguishing the transduced from untransduced cells (Figure 13A).  
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Figure 12 Illustration of the experimental system to study B-cell development 
in vitro 
Fetal liver cells (CD45.2) from Ebf1-deficient mouse embryos (E14.5-E16.5) were 
infected by co-culture with transduced GP+E86 cells over two days. Afterwards, the 
fetal liver cells were co-cultured for 10 to 14 days with Whitlock-Witte cells (CD45.1). 
This was followed by analysis of B-cell development via flow cytometry.  
 
 
As Pongubala et al. (2008) described, the ectopic expression of βEbf1 in Ebf1-
deficient fetal liver cells restores B cell differentiation. In my study, the ectopic 
expression of βEbf1 in Ebf1-deficient fetal liver cells could restore around 70% 
CD19-positive transduced cells compared to mock transduced cells. The ectopic 
expression of Ebf1-S13A, -S14A, -S13, 14A, αEbf1, Ebf1-ΔTAD, and αEbf1-ΔTAD 
cannot increase the percentage of CD19-positive cells (⁓ 5%) compared to mock 
transduced cells. This data shows an arrest in B cell differentiation upon ectopic 
expression of αEbf1 or without expression of serine 13, 14 or TAD of wild type Ebf1 
(Figure 13B). 
 
To further control the retroviral transduction and WW co-culture, GFP and CD45.2 
double positive cells were purified by flow cytometry and investigated for expression 
of Ebf1 and CD19 mRNA. No significant difference Ebf1 mRNA expression was 
detected between all expressions of the different versions of α and βEbf1. 
The expression of CD19 was significantly decreased in fetal liver cells expressing 
αEbf1 or modified versions of Ebf1 compared to βEbf1 (Figure 13C) 
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Figure 13 Serine 13, 14 and transactivation domain of Ebf1 are required for B-
cell development 
 (A) Flow cytometry analysis of B-cell differentiation of transduced Ebf1-deficient fetal 
liver cells (CD45.2). The percentage of CD19+ cells was analysed to monitor B-cell 
differentiation. Cells are gated for FCS/SSC, PI-, CD45.2+ and GFP+. CD45.2+ and 
GFP+ cells are transduced fetal liver cells from Ebf1-deficient mouse embryos 
(E14.5-E16.5). Mock is empty MIG vector. n = 3. 
(B) Percentage of CD19+ cells of transduced fetal liver cells corresponding to panel 
(A). ** p < 0.005; n = 3. 
(C) Determination of Ebf1 and CD19 transcripts of transduced fetal liver cells 
(CD45.2+, GFP+) corresponding to panel (A). After WW co-culture, GFP and CD45.2 
double positive cells were purified by flow cytometry for analysis by qPCR. * p < 0.05, 
** p < 0.005; n = 3.   
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4.3 Ebf1 serine 13 and serine 14 are not required for DNA binding  
Hagman et al. (1991) and Feldhaus et al. (1992) established that Ebf1 binds to the 
nucleotide sequence 5-CAAGGGAAT-3 found in the mb-1 promoter. To study the 
DNA binding activity of Ebf1-S13A, -S14A and -S13, 14A, electrophoretic mobility shift 
assay (EMSA) were performed. In the binding reaction, the cell protein lysates of 
transfected Ba/F3 cells were used. The Ba/F3 cells were transiently transfected with 
pcDNA3.1-flag-βEbf1, Ebf1-S13A, -S14A and -S13, 14A. The empty vector as used as a 
negative control.  
 
 
 
 
Figure 14 Serine 13 and serine 14 of Ebf1 are not required for DNA binding 
Representative electrophoretic mobility shift assay of cell lysates from transiently 
transfected Ba/F3 cells with pcDNA3.1-mock-Flag, -Ebf1-Flag, Ebf1-S13A-Flag, Ebf1-
S14A-Flag or Ebf1-S13, 14A-Flag. Mb-1 32P-alpha-dCTP: radiolabeled oligonucleotide. 
Unlabelled Mb-1: non-radioactively labelled oligonucleotide. Lower band shows DNA 
and protein complex obtained. Higher band shows flag antibody binding to DNA and 
protein complex. At the bottom of the gel is free oligonucleotide. n = 3.  
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The EMSA data shows that the binding activity of mutant Ebf1 to the Mb-1 promoter-
binding site is comparable to wild type Ebf1. The binding specificity was detected by 
competition with a non-radioactively labelled oligonucleotide, as well as by adding 
anti-flag antibody. The specific binding of this antibody to the Ebf1-flag: DNA 
complex slows down running behaviour of the complex in the gel (super shift, Figure 
14).  
 
4.4 Transactivation of Ebf1 depends on serine 13 and serine 14 
The lambda5 promoter has been established as a model for the transactivation 
potential of Ebf1 in Ba/F3 cells (Sigvardsson et al. 2002). The murine pro-B cell line, 
Ba/F3 is particularly suitable for the luciferase reporter assay because the amount of 
Ebf1 in Ba/F3 cells is undetectable (Dr. Inga Ludenberg).  
 
To study the transactivation potential of Ebf1 influenced by modifications of serine 13 
and 14, wild type αEbf1 and the TAD, luciferase reporter assays were performed. 
pCMV- mock, βEbf1, Ebf1-S13A, Ebf1-S14A, Ebf1-S13,14A, αEbf1, βEbf1-ΔTAD and 
αEbf1-ΔTAD were separately transiently transfected with reporter construct pBL-
Lambda5-Luc (Sigvardsson et al. 2002) into Ba/F3 cells. This reporter plasmid 
contains the lambda5 promoter including three Ebf1-binding sites in front of the 
luciferase reporter gene (Figure 15A). To normalize the luciferase activity, the Ba/F3 
cells were additionally transfected with the pCMV- LacZ plasmid.  
 
The relative induction of the lambda5 promoter was measured by luciferase activity 
48 hours after transfection (Figure 15B). The transfection of Ba/F3 cells with βEbf1 
activates the lambda5 promoter ∼ 25 folds, while the transactivation with modified 
Ebf1 was approximately ∼ 5 folds reduced (Ebf1-S13A: 2.97 folds, Ebf1-S14A: 4.86 
folds, Ebf1-S13,14A: 4.42 folds, αEbf1: 8 folds, Ebf1-ΔTAD: 4.97 folds and αEbf1-
ΔTAD: 4.09 folds activation of lambda5 promoter). Thus, the inductions were 
significantly affected by mutation of serine 13, serine 14 and αEbf1, as well as Ebf1-
ΔTAD and αEbf1-ΔTAD. 
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Figure 15 Transactivation of Ebf1 depends on serine 13, serine 14 and the 
transactivation domain 
 (A) Schematic diagram of the luciferase reporter assay. Ebf1 is expressed from 
pCMVcyto plasmids. The reporter plasmid contains the lambda5 promoter including 
three Ebf1 binding sites and the luciferase gene (pBL-Lambda5-Luc).  
(B) Relative induction of Lambda5 promoter was measured by luciferase activity 24 
hours after transfection in Ba/F3 cells transfected with pCMV-, mock, Ebf1, Ebf1-
S13A, Ebf1-S14A, Ebf1-S13,14A, αEbf1, Ebf1-ΔTAD and αEbf1-ΔTAD. Luciferase 
values were first normalized to β-galactosidase activity and then to the luciferase 
activity in cells transfected with the empty pCMVcyto plasmid (pCMV-mock).  * p < 
0.05, ** p < 0.005; n = 4.  
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4.5 Expression of Ebf1 target genes requires serine 13 and serine 
14 
Ebf1 is a transcription factor that influences the expression of many B cell genes. 
Loss of Ebf1 leads to the down-regulation or loss of mRNAs for λ5, Pax5, mb-1, B29, 
VpreB and Rag1 in common lymphoid progenitor cells (Zandi et al. 2010). 
 
To investigate the influence of serine13 and serine14 phosphorylation and the 
importance of the TAD, the expression of B lineage genes were analysed by real-
time PCR in transduced Ebf1 deficient fetal liver cells. After 10 – 14 days WW co-
culture (Figure 12) GFP and CD45.2 double positive cells were sorted by flow 
cytometry and the mRNA expression of λ5, Pax5, mb1, B29, VpreB, Rag1 and E2A 
were investigated by real time PCR. λ5 is expressed around 25-fold higher in wild 
type βEbf1 transduced fetal liver cells, compared to only 1-2-fold in αEbf1 and all 
modified Ebf1 transduced fetal liver cells. Pax5 is expressed 8-fold higher in βEbf1 
transduced cells compared to less than 1-fold in S13A, S14A, S13, 14A and Ebf1-ΔTAD, 
and 2-fold in αEbf1 and αEbf1-ΔTAD transduced fetal liver cells. mb1 is expressed 
11.5-fold higher in βEbf1 transduced fetal liver cells, compared to less than 2-fold in 
all modified Ebf1 transduced fetal liver cells. The expression of B29 in wild type Ebf1 
transduced cells is 11.7-fold higher compared to only 4-5-fold in S13A, S14A and S13, 
14A and less than 1 fold in αEbf1, Ebf1-ΔTAD and αEbf1-ΔTAD transduced fetal liver 
cells. VpreB shows 21-fold higher expression in βEbf1 transduced fetal liver cells, 
compared to 1-fold in S13A, αEbf1, Ebf1-ΔTAD and αEbf1-ΔTAD and around 10-folds 
in S14A and S13, 14A.  
 
The expression of Rag1 is induced approximately 3-fold by βEbf1 as well as by 
αEbf1 and all modified versions of Ebf1 in transduced fetal liver cells.  Similarly, E2A 
is induced approximately 1-fold by βEbf1 and αEbf1 and all modified Ebf1 versions. 
The mRNA expression of Ebf1 downstream B lineage genes are significantly 
reduced, but Rag1 and E2A are not affected by α or βEbf1 or any of the 
modifications.  
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Figure 16 Expression of Ebf1 target genes requires serine 13, serine 14 and the 
transactivation domain of Ebf1 
Quantitative RT-PCR analysis of indicated genes in sorted transduced fetal liver cells 
from Ebf1-deficient mouse (CD45.2+, GFP+) after 10 days of WW-culture 
corresponding to Figure 12 and Figure 13 panel (A). The fetal liver cells were 
transduced with Ebf1, Ebf1-S13A, Ebf1-S14A, Ebf1-S13,14A, αEbf1, Ebf1-ΔTAD and 
αEbf1-ΔTAD. Mock is empty MIG vector. * p < 0,05; n = 3.  
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4.6 D-J rearrangement requires Ebf1 but is independent of serine 
13, 14 and TAD 
D-J rearrangement of immunoglobulin heavy chain locus is absent in Ebf1-deficient 
common lymphoid progenitor cells (Reynaud et al. 2008, Bassing et al. 2000, Lin and 
Grosschedl 1995).  
 
To study whether the D-J IgH locus rearrangement is influenced by the modification 
of serine 13, serine 14, αEbf1, βEbf1-ΔTAD and αEbf1-ΔTAD, PCR was performed 
with transduced Ebf1-deficient fetal liver cells. After 10 – 14 days WW co-culture 
(Figure 12) GFP and CD45.2 double positive cells were sorted by flow cytometry and 
the D-J rearrangement at the IgH locus was analysed. Using DH5-2 and JH4 primer 
flanking the D and J regions of the genomic DNA, the products result in a “ladder” of 
4 bands corresponding to the joints DJ1, DJ2, DJ3 and DJ4 (Figure 17A, B and C).  
 
βEbf1, βEbf1-S13A, βEbf1-S14A, βEbf1-S13,14A (Figure 17B), αEbf1, βEbf1-ΔTAD and 
αEbf1-ΔTAD (Figure 17C) transduced Ebf1-deficient fetal liver cells exhibited all 
bands corresponding to the DJ1, DJ2, DJ3, DJ4 and germline which means that the 
modification of serine 13 and 14, αEbf1 and TAD do not influence D-J IgH 
rearrangements during B cell development.  
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Figure 17 D-J Rearrangement of the immunoglobulin heavy chain locus 
requires Ebf1, but is independent of serine 13, serine 14 and the 
transactivation domain 
(A) Schematic diagram of the D-J IgH locus and the primers flanking the DH5-2 and 
JH4 regions used for the amplification of genomic DNA. 
(B and C) Sorted transduced fetal liver cells from Ebf1-deficient mouse embryos 
(CD45.2+, GFP+) after 10-14d co-culture with Whitlock-Witte cells were examined for 
D-J rearrangement by PCR. The fetal liver cells were transduced with βEbf1, Ebf1-
S13A, Ebf1-S14A, Ebf1-S13,14A (B), αEbf1, Ebf1-ΔTAD and αEbf1-ΔTAD (C). Arrows 
indicate germline (GL) DNA and rearrangements of D to J1, J2, J3 or J4. n = 3. 
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4.7 Generation of antibodies specific for phosphorylated serine 13 
and serine 14 of Ebf1 
To confirm the phosphorylation of Ebf1 at serine13 and serine14 identified by mass 
spectrometry (Dr. Gerald Burgstaller, Dr. Hakan Sarioglu) and to be able to study the 
dynamics of this modification, we wanted to generate monoclonal antibodies 
recognizing the phosphorylated serine13 and serine 14 of Ebf1. This task was 
conducted with the cooperation of Dr. Elisabeth Kremmer (Inst. for Molecular 
Immunology, HMGU Munich). We also included non-phospho specific peptide 
sequences. The peptide sequence is SIQRSGS(p)S(p)MKEEPC, which locates from 
amino acid 7 to 19 of Ebf1 (Figure 18A). The C-terminal cysteine was added to allow 
coupling of the peptide.  
 
Totally, 60 monoclonal antibodies were generated. To analyse these clones by 
western blot, proteins were isolated from the Ebf1 expressing pre-B cell line 18-81 
TK+, which also has been used to determine the post-translational modifications of 
Ebf1 by mass spectrometry.  The protein extract was split and one half treated with 
calf intestinal alkaline phosphatase (CIP), to remove potential phosphorylation.  CIP 
treated and non-treated proteins were blotted on nitrocellulose membrane and tested 
with the newly generated antibodies by immuno-detection.  
 
The supernatants of two monoclonal hybridoma clones, 14H6 and 1C4, could 
recognise CIP-untreated but not CIP-treated protein extracts (Figure 18B). 14H6 
represents an Ebf1-S13 (P) specific antibody and 1C4 represents an Ebf1-S13 (P) S14 
(P) specific antibody. The supernatants of hybridoma clones 1E12 could recognize 
both CIP-treated and CIP-untreated protein extracts. Therefore, it is a non-phospho 
specific antibody used as a control in further experiment. As expected, the CIP-
treated protein extracts in which phospho-groups were removed, show a lower 
molecular weight band compared to the untreated protein extracts (Figure 18B). 
Therefore, we conclude that endogenous Ebf1 of 18-81 TK+ cells is phosphorylated 
at serine13 and serine14 corresponding to the mass spectrometry data from Dr. 
Gerald Burgstaller and Dr. Hakan Sarioglu. 
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Figure 18 Generation of antibodies specific for phosphorylated serine 13 and 
serine 14 of Ebf1 
(A) Schematic overview of the position and the sequence of the peptide used to 
generate Ebf1-S13 (P), and Ebf1-S13 (P) S14 (P) specific antibodies. The synthetic 
peptide locates from amino acids 7 to 19. p: phospho-specific antibody; np: non-
phospho antibody. 
(B) Representative western blot analysis for CIP-treated protein extract from 18-81 
TK+ cells using Ebf1 phosphorylation specific or unspecific antibodies (clone 14H6, 
1C4 and 1E12). +: CIP-treated protein extracts, -: CIP-untreated protein extracts. 
CIP-untreated protein extracts were used as a negative control. Actin was used as a 
loading control. n = 3  
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5 Discussion 
5.1 Verification of Ebf1-S13 and S14 phosphorylation  
Ebf1 is a key regulator of early B-cell differentiation participating in a complex 
regulatory network. Ebf1 is expressed already in CLPs, and the functional activity of 
Ebf1 is required for the generation of pro-B cells (fraction B cells) that undergo the 
rearrangement of immunoglobulin heavy chain genes (Lin and Grosschedl 1995). 
Genome-wide ChIP-seq analysis in pro-B cells showed that Ebf1 occupies regulatory 
sequences of about 3000 genes, which are strongly associated with B cell identity 
and the (pre-)BCR signaling cascade (Treiber et al. 2010b). Ebf1 can activate, 
repress or poise those targets during B cell development raising the question how 
these biochemically very different activities are achieved. A possibility to explain 
these different behaviours is post-translational protein modification.  
Therefore, transiently transfected Ebf1-flag was purified from the murine pre-B cell 
line 18-81 TK+ and HEK293T cells via immunoprecipitation and mass spectrometry 
was performed. The data shows that Ebf1-S13 and S14 are phosphorylated and this 
phosphorylation is present only in 18-81 TK+ cells, but not HEK293T cells, 
demonstrating cell-type specificity. Phosphorylation can regulate activation, 
localization and interaction with other proteins. For example the transcription factor 
E2A, which mediates the specification of the B cell lineage in cooperation with Ebf1, 
needs to be phosphorylated during B cell development (Sloan et al. 1996). 
Therefore, phosphorylation of Ebf1-S13 and S14 might be important biologically and 
biochemically for the various functions of Ebf1 during B cell development.  
 
To confirm the finding from mass spectrometry independently on endogenous Ebf1 in 
cells, we tried to generate monoclonal antibodies. The peptide sequence used for 
antibody production is SIQRSGS(p)S(p)MKEEPC, located from amino acid 7 to 19 of 
Ebf1 (Figure 18). 14H6 is an Ebf1-S13P specific antibody and 1C4 is an Ebf1-
S13PS14P specific antibody. In this study, endogenous protein was isolated from 18-
81 TK+ cells, and the phosphorylation of Ebf1-S13 and S14 were detected via western 
blot using the newly generated monoclonal antibodies 14H6 and 1C4. In this western 
blot, the phospho-specific detection of S13 and S14 was controlled via treatment with 
calf intestinal phosphatase, which leads to the removal of phospho-groups. Our data 
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shows that endogenous serine 13 and 14 of Ebf1 are phosphorylated, confirming the 
mass spectrometry data.  
 
The mass spectrometry on transiently transfected Ebf1-flag also shows that 
approximately half of Ebf1 protein is phosphorylated at S13 and S14 in 18-81 TK+ 
cells showing flexibility in the biochemical properties of Ebf1 and thus offering 
potential explanation. Compared to other Ebf family members, which are expressed 
in tissues unrelated to hematopoietic cells, none of them present a serine at or close 
to this position. This could be another indirect evidence to support our conclusion 
that phosphorylation of Ebf1-S13 and S14 is cell-type specific.  
 
The expression of Ebf1 is mediated via two distinct promoters, the distal α-promoter 
and the proximal β-promoter. Transcription from these promoters results in the 
expression of two Ebf1 isoforms, αEbf1 and βEbf1. Due to alternative splicing, 
transcripts from the distal promoter use a different start codon compared to βEbf1, 
generating an isoform that lacks 14 N-terminal amino acids of the βEbf1 isoform. 
Therefore, the phosphorylation of this two positions might also help to resolve 
potentially different functions between α and βEbf1 during B cell development. 
 
5.2 The biological function of Ebf1-S13, S14-phosphorylation during B 
cell development 
As a key regulator, Ebf1 plays a ‘pioneer’ role for B cell development (Hagman and 
Lukin 2005). Ebf1-deficient mice display a complete block of B lymphopoiesis at the 
pre-pro-B-cell (fraction A) stage. No rearrangement at the Igµ locus is detected in 
vivo, and Ebf1-deficient CLP show no D-to-JH rearrangement (Pongubala et al. 
2008). The ectopic expression of Ebf1 in hematopoietic progenitors from the fetal 
liver of Ebf1-deficient mice could restore B cell development (Pongubala et al. 2008). 
Since we found the phosphorylation of Ebf1-S13 and S14 specifically in B cells, we 
continued to study the potential biological functions of this two position. We 
generated Ebf1-S13A, S14A and S13,14A via site-directed mutagenesis at serine 13 
and 14 replacing the serine residues with alanine. Serine has a hydroxyl group that 
can be phosphorylated by kinases, which is missing in the structurally similar alanine. 
However, this mutagenesis should not change the native structure. Our western blot 
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shows that the expression of Ebf1-S13A, S14A and S13,14A is comparable to wild type 
Ebf1 in HEK293T cells suggesting that the mutagenesis does not change the stability 
of native protein (Figure 11b). As a transcription factor, Ebf1 protein forms a dimer 
and binds to DNA via its DBD. Our EMSA assays show that the binding activity of 
mutant Ebf1 to its binding site in the mb-1 promoter is comparable to wild type Ebf1 
(Figure 14). Therefore, the phosphorylation of S13 and 14 is not associated with 
DNA binding activity of Ebf1. It also demonstrates that the mutant versions of Ebf1 
are folded correctly, otherwise no DNA binding should be observed.  
 
To investigate the biological function of the phosphorylation of Ebf1, Ebf1-S13A, -S14A 
and -S13,14A are analysed by an established long-term cell culture system that 
supports B cell differentiation of primary hematopoietic cells in vitro (WW culture). 
Mutant versions of Ebf1 are introduced into Ebf1-/- fetal liver cells via a co-culture 
with retrovirus producing GP+E cells. The transduced fetal liver cells undergo 10-14 
days of co-culture with hematopoietic cells to allow B cell development. We use 
CD19 to identify B cell development as CD19 is a surface antigen from the pro-B cell 
stage on (fraction B). Our data shows that only 2%-8% cells express CD19 upon 
reintroduction of Ebf1-S13A, S14A and S13,14A, compared to wild type Ebf1. Therefore, 
the phosphorylation of serine 13 and 14 of Ebf1 are required for B cell development. 
This data is confirmed via analysis of CD19 mRNA expression. Transduced Ebf1-/- 
fetal liver cells are sorted and analysed via real time-PCR, which shows that the 
expression of CD19 mRNA is significantly decreased in cells expressing Ebf1-S13A, 
S14A and S13,14A.  
 
D-J rearrangement of the immunoglobulin heavy chain locus is absent in Ebf1-
deficient common lymphoid progenitor cells (Reynaud et al. 2008, Lin and 
Grosschedl 1995). This study shows that after 10-14 days WW culture, DJH 
rearrangement is detectable not only in wild-type Ebf1 transduced fetal liver cells, but 
also in Ebf1-S13A, S14A and S13,14A expressing cells, suggesting that DJH is 
independent of the phosphorylation of serine 13 and 14 (Figure 17). Furthermore, 
this confirms the functionality of the mutant versions of Ebf1, since they are able to 
rescue part of the defects of Ebf1-deficient cells. DJH rearrangement is regulated by 
Ebf1 via the induction of RAG genes. Therefore the expression of RAG gene has 
also been studied. After 10-14 days WW culture, the transduced Ebf1-/- fetal liver 
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cells were sorted and analysed via real time-PCR. Our data shows that the mRNA 
expression of Rag1 in fetal liver cells expressing mutant versions of Ebf1 is 
comparable to wild type Ebf1, which corresponds to the DJH rearrangement. This 
could be one of the reasons for the diversity of Ebf1, which means not all of its 
functions are dependent on phosphorylation.  
 
The double mutation, Ebf1-S13S14A, does not show a synergistic effect in enhancing 
the block of B cell development, as well as in the expression of target genes. In 
contrast, a few more percentage of CD19+ cells is present upon double mutation 
suggesting an overlap between the biological functions of phosphorylated Ebf1-S13 
and Ebf1-S14. The data is confirmed by mRNA expression of CD19 isolated from 
Ebf1-S13S14A transfected fetal liver cells (Figure 13C). The decrease of CD19 mRNA 
is similar in Ebf1-S13S14A and Ebf1-S13A transfected cells where S14 seems to have 
a reduced effect, revealing a dominant effect of S13 in this case.   
 
The fundamental phenotypes of Ebf1-/- hematopoietic cells are a complete block of B 
cell development in fraction A and a lack of DJH rearrangement in CLP. During our in 
vitro experiment, we show that the early B cells need the phosphorylation of Ebf1 at 
S13 and S14 to develop into fraction B. The same phenotypes also occur upon 
deletion of the transactivation domain (Ebf1-ΔTAD and αEbf1-ΔTAD) suggesting the 
possibility that the block of B cell development caused by mutant Ebf1 is related to 
the transactivation.  
 
To study whether the transactivation potential of Ebf1 is influenced by modifications 
of serine 13 and 14, luciferase reporter assays were performed. We used a pre-B cell 
line, Ba/F3 cells, which does not express Ebf1 (Smith et al. 2002). βEbf1, Ebf1-S13A, 
Ebf1-S14A and Ebf1-S13,14A were transfected with a reporter construct containing the 
λ5 promoter including three Ebf1-binding sites in front of the luciferase reporter gene 
(Figure 15A; Sigvardsson et al. 1997). Our data shows that the inductions were 
significantly affected by the mutation of serine 13 and serine 14, suggesting that the 
transactivation of the λ5 promoter depends on the phosphorylation of Ebf1-S13 and 
S14.  Our study reveals important differences in Ebf1 transactivation. Phosphorylation 
of S13 and S14 in Ebf1 is required to activate the λ5 promoter in B cells involved in 
pre-BCR signaling cascades, but Ebf1 transactivation is only partially phospho-
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dependent. For example, the mRNA level of Rag1, which is directly participating in 
the Ig rearrangement, is comparable between wild type and mutant versions of Ebf1 
in primary B cell culture. This might be because the Rag1 promoter differs 
structurally from the λ5 promoter. Ebf1 can bind on the Rag1 promoter and co-
operate with other components to trans-activate Rag1, which does not require the 
phosphorylation of Ebf1-S13 and S14. Another reason for the differences in Ebf1 
transactivation might be the two Ebf1 isoforms. The first expressed isoform of Ebf1 is 
αEbf1 in CLPs, where the D-JH rearrange starts (Roessler et al. 2007b). αEbf1 lacks 
the first 14 amino acids, including S13 and S14. Therefore a subset of Ebf1 target 
genes, initiated by αEbf1 in CLPs seems to be independent of S13 and S14 
phosphorylation. In our λ5 promoter transactivation experiment, we also studied 
αEbf1, which showed that the induction by αEbf1 is significantly decreased 
compared to βEbf1. This data suggests that the two isoforms of Ebf1 are functional 
different. However concerning co-transactivation together with E2A, similar activation 
of the endogenous λ5 gene was observed with αEbf1 and βEbf1 suggesting that both 
isoforms can synergise with E2A (Roessler et al. 2007b).  
 
5.3 The regulation of Ebf1 by phosphorylation of S13 and S14 during 
B cell development 
Early B-cell differentiation is a highly regulated process in which a multipotential 
progenitor cell is converted into a cell that expresses the B-cell antigen receptor. 
Several transcription factors and signaling pathways have been implicated in the 
regulation of this process. The targeted inactivations of the Ebf1 and E2A genes 
result in similar blocks of B-cell differentiation, preceding the onset of rearrangement 
of the immunoglobulin heavy chain DH and JH segments (Bain et al. 1994, Zhuang et 
al. 1994b, Lin and Grosschedl 1995). Forced expression of Ebf1 in hematopoietic 
progenitor cells skews the differentiation along the B-cell pathway, and genetic 
bypass experiments have shown that Ebf1 can promote B-cell differentiation in E2A-/- 
hematopoietic progenitors (Medina et al. 2004, Seet et al. 2004). Another important 
event in the differentiation of B-lineage cells, the commitment step, is regulated by 
the transcription factor Pax5. Pax5-deficient mice generate pro-B cells that express 
early B-cell markers and undergo D-to-JH and proximal VH -to-DJH rearrangements 
(Nutt et al. 1999). Pax5 is also required continuously for the maintenance of B-cell 
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identity (Rolink et al. 1999a). The analysis of the regulatory hierarchy of transcription 
factors has suggested that E2A activates the expression of Ebf1 and, together, both 
transcription factors induce the expression of several B-lineage genes, including 
Rag1, Pax5, λ5, VpreB, B29 and mb1, which encode components of the pre-B-cell 
receptor (O'Riordan and Grosschedl 1999).  
 
Since we found that phosphorylation of Ebf1 at S13 and 14 influences B cell 
development via transactivation of the λ5 promoter, we further investigated 
downstream genes. After 10-14 days WW co-culture, the transduced Ebf1-/- fetal liver 
cells were sorted and analysed via real time-PCR. Our data shows that the 
expression of Pax5, λ5, VpreB, B29 and mb1 is significantly decreased in cells 
expressing Ebf1-S13A, S14A, S13,14A as well as αEbf1 or Ebf1-ΔTAD indicating that 
the expression of these B lineages genes is associated with the phosphorylation of 
S13 and 14. However the expression of Rag1 is comparable between α, β and 
modified versions of Ebf1, as discussed before (5.2). 
 
Ebf1 and E2A appear to synergize in the activation of B-lineage gene expression 
because Ebf1/E2A double-heterozygous mutant mice have a more severe defect in 
B-cell differentiation than the single-heterozygous mice (O'Riordan and Grosschedl 
1999). Therefore, we also studied the expression of E2A. The data shows no 
significant difference in the expression of E2A in cells expressing Ebf1-S13A, S14A, 
S13,14A, αEbf1, Ebf1-ΔTAD and αEbf1-ΔTAD. The expression of E2A is initiated 
upstream of Ebf1 (Seet et al. 2004), however, the expression of E2A is impaired in 
Ebf1-deficient mice, suggesting that Ebf1 may also regulate the expression of E2A 
(Zhuang et al. 2004). Therefore, as with the Rag1 gene, E2A may be regulated via 
αEbf1 in CLP. 
 
Taken together, the expression of E2A is regulated via αEbf1, and E2A co-operates 
with αEbf1 to mediate gene expression in CLP. The expression of Pax5, λ5, VpreB, 
B29 and mb1 is regulated by the co-activation of E2A and βEbf1 depending on the 
phosphorylation at serine13 and 14, which means the two isoforms of Ebf1 are 
functionally different in the downstream expression and this difference might occur at 
different stages of B cell development. This data also shows that part of the target 
genes require the phosphorylation of serine 13 and 14 in Ebf1, giving a potential 
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explanation for the precise timing in the expression of Ebf1 targets during B cell 
development.  
 
5.4 Two isoforms of Ebf1 are functionally different during B cell 
development 
The expression of the Ebf1 gene involves two promoters (distal promoter α and 
proximal promoter β) that are differentially regulated and generate distinct protein 
isoforms (αEbf1 and βEbf1). Transcription from the α promoter results in the 
expression of αEbf1, generating an isoform that lacks 14 N-terminal amino acids of 
βEbf1 (Roessler, Budhu and Wang 2007a). However, no functional difference 
between the two Ebf1 isoforms has yet been described. The α promoter is directly 
regulated by E2A and indirectly regulated by the IL-7 receptor. IL-7 signaling 
activates Ebf1 expression indirectly by providing permissive conditions for Ebf1 
activation by other factors (Boller and Grosschedl 2014). IL-7 deficient mice show a 
developmental arrest at the CLP stage and impaired Ebf1 expression (Roessler et al. 
2007b, Kikuchi et al. 2005).  Forced expression of Ebf1 can partially rescue B-cell 
development in IL-7R-deficient mice (Kikuchi et al. 2005). The expression of βEbf1 is 
regulated by Ets1, Runx1, Pax5 and PU.1 (Roessler et al. 2007b). Runx1 can 
change the epigenetic landscape at the Ebf1 β promoter (Seo et al. 2012). Recent 
studies show that the SWI/SNF complex, which is associated with the epigenetic 
regulation of Ebf1, facilitates transcription from the Ebf1 β promoter.  
 
Since S13 and 14 only appear in βEbf1, the modification of these two positions open 
a new view of the biological function of the two Ebf1 isoforms. In our WW co-culture, 
B cell development shows a strong impairment in αEbf1 expressing cells, while 
βEbf1 can rescue the Ebf1-/- hematopoietic cells developing into B cells. This data 
suggests that αEbf1 and βEbf1 are functionally different. αEbf1 starts to be 
expressed from the middle stage of CLP (ly6d-, Rag1+; P, Joseph and Jacob 2012)  
synergising with E2A in inducing the expression of Rag1, which mediates the DJH 
rearrangement. αEbf1 can support the development of CLPs to the pre-pro-B stage 
(fraction A), and then βEbf1 is required for further B cell development. Our study of 
Ebf1 targets shows that B lineage genes (Pax5, λ5, mb1, B29 and VpreB) are 
regulated by βEbf1 in a S13 and S14 phosphorylation-dependent manner. Pax5 
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maintains the B lineage from pro-B stage (fraction B) on (Nutt et al. 1997b). 
Therefore βEbf1 starts to regulate B cell development from pro-B stage. λ5, mb1, 
B29 and VpreB are the components of pre-BCR, which regulate the pre-B cell 
proliferation and development. Therefore βEbf1 maintains B lineage in a 
phosphorylation of S13 and S14 dependent manner at least from the pro-B cell stage 
(Figure 19). 
 
 
 
 
 
Figure 19 Representation of the expression of Ebf1 isoforms and 
corresponding target genes from HSC to pro-B cells 
CLP are separated into three developmental stages. Expression of αEbf1 starts from 
the middle stage of CLP till pre-pro-B cells and regulates the expression of E2A and 
Rag1, allowing DJH rearrangement. Expression of βEbf1 starts from pro-B cells in a 
S13 and S14 phosphorylation dependent manner and regulates the expression of 
Pax5, λ5, VpreB, mb-1, B29 and CD19. HSC: hematopoietic stem cell; MPP: multi-
potential progenitor; CLP: common lymphoid progenitor. 
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5.5 Future work 
The regulation of Ebf1 target genes requires collaboration of Ebf1 with other 
transcription factors. Many Ebf1-regulated genes, including Vpreb1, Igll1, and CD79a 
contain binding sites for E2A (Treiber et al. 2010b). However, during B cell 
development additional Ebf1-occupied sites are gained while others are lost resulting 
in a shift in the composition of neighboring binding sites between pro-B and mature B 
cells (Gyory et al. 2012). Our data shows that in the pre-B cell line Ba/F3 cells, the 
phosphorylation of Ebf1-S13 and S14 are required for the transactivation of λ5. For the 
future work, to further prove the biochemical function of the phosphorylation of Ebf1-
S13 and S14, the co-transactivation between E2A and Ebf1-S13A and S14A should be 
studied.  
 
Ebf1 plays different role during B cell development. It regulates the Ig rearrangement 
and the expression of B lineage genes (Lin and Grosschedl 1995). Our data shows 
that the development of CLPs to pre-pro-B cells is mediated via αEbf1, and then 
βEbf1 starts to regulate pro-B development into pre-B cells in a S13 and S14 
dependent manner. However, the regulation of the phosphorylation of Ebf1 at S13 
and S14 in mature B is unclear. We generated Ebf1-S13 and S14 specific antibodies, 
14H6 and 1C4, which can be used to detect at later stages of B cell development the 
phosphorylation states of S13 and S14.  
 
The expression of 3000 Ebf1 target genes is regulated by Ebf1 in three different 
ways: activation, repression and poising (Treiber et al. 2010b). We studied activation 
of the targets Pax5, λ5, mb1, CD19 VpreB, Rag1 and E2A, and found the expression 
of Pax5, λ5, mb1, CD19 and VpreB associated with the phosphorylation of Ebf1-S13 
and S14. For the future work, the repressed and poised genes should also be studied 
in Ebf1-S13A and S14A expressing cells to open a new view of the multi-function of 
Ebf1 during B cell development. 
 
RSK and cdc2 are candidates to regulate the phosphorylation of Ebf-S13, and CKII 
and PKC potentially regulate the phosphorylation of Ebf1-S14 (NerPhosK 1.0 Server, 
Technical University of Denmark). Since we found that the phosphorylation of Ebf1-
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S13 and S14 plays an important role during B cell development, the kinases 
responsible for this PTM and this regulation should be characterized. 
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